10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-35331

ACADIA HEALTHCARE COMPANY, INC.

(Exact name of registrant as specified in its charter)

Delaware	45-2492228
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

6100 Tower Circle, Suite 1000

Franklin, Tennessee 37067

(Address, including zip code, of registrant’s principal executive offices)

(615) 861-6000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of August 5, 2015, there were 71,637,097 shares of the registrant’s common stock outstanding.

ACADIA HEALTHCARE COMPANY, INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets (Unaudited) as of June 30, 2015 and December 31, 2014	1
	Condensed Consolidated Statements of Income (Unaudited) for the Three and Six Months Ended June  30, 2015 and 2014	2
	Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the Three and Six Months Ended June 30, 2015 and 2014	3
	Condensed Consolidated Statement of Equity (Unaudited) for the Six Months Ended June 30, 2015	4
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2015 and 2014	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
Item 4.	Controls and Procedures	39
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	41
Item 1A.	Risk Factors	41
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 6.	Exhibits	41
SIGNATURES

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Acadia Healthcare Company, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

	June 30, 2015			December 31, 2014
	(In thousands, except share and per share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	34,572		$	94,040
Accounts receivable, net of allowance for doubtful accounts of $26,233 and $22,449, respectively		182,315			118,378
Deferred tax assets		38,693			20,155
Other current assets		70,325			41,570
Total current assets		325,905			274,143
Property and equipment, net		1,455,390			1,069,700
Goodwill		1,946,028			802,986
Intangible assets, net		58,514			21,636
Deferred tax assets – noncurrent		33,966			13,141
Other assets		106,582			41,984
Total assets	$	3,926,385		$	2,223,590
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt	$	38,652		$	26,965
Accounts payable		58,714			48,696
Accrued salaries and benefits		77,545			59,317
Other accrued liabilities		68,197			30,956
Total current liabilities		243,108			165,934
Long-term debt		1,914,555			1,069,305
Deferred tax liabilities – noncurrent		20,200			63,880
Other liabilities		82,218			43,506
Total liabilities		2,260,081			1,342,625
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued		—			—
Common stock, $0.01 par value; 90,000,000 shares authorized; 70,596,523 and 59,211,859 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively		706			592
Additional paid-in capital		1,567,304			847,301
Accumulated other comprehensive loss		(51,586	)		(68,370	)
Retained earnings		149,880			101,442
Total equity		1,666,304			880,965
Total liabilities and equity	$	3,926,385		$	2,223,590

See accompanying notes.

1

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
	(In thousands, except per share amounts)
Revenue before provision for doubtful accounts	$	461,798		$	220,664		$	835,956		$	426,783
Provision for doubtful accounts		(8,138	)		(6,861	)		(16,513	)		(11,562	)
Revenue		453,660			213,803			819,443			415,221
Salaries, wages and benefits (including equity-based compensation expense of $5,355, $2,406, $9,249 and $4,170, respectively)		243,302			122,473			449,173			240,048
Professional fees		30,029			10,891			52,456			21,273
Supplies		20,542			10,596			36,796			20,660
Rents and leases		8,211			2,889			14,097			5,658
Other operating expenses		51,128			24,646			91,655			47,756
Depreciation and amortization		14,926			5,935			28,030			11,371
Interest expense, net		28,049			9,730			50,195			19,437
Loss (gain) on foreign currency derivatives		961			(13,735	)		908			(13,735	)
Transaction-related expenses		7,157			3,016			25,573			4,595
Total expenses		404,305			176,441			748,883			357,063
Income from continuing operations before income taxes		49,355			37,362			70,560			58,158
Provision for income taxes		15,512			14,905			22,125			22,680
Income from continuing operations		33,843			22,457			48,435			35,478
Income (loss) from discontinued operations, net of income taxes		1			(6	)		3			31
Net income	$	33,844		$	22,451		$	48,438		$	35,509
Basic earnings per share:
Income from continuing operations	$	0.50		$	0.43		$	0.74		$	0.70
Income (loss) from discontinued operations		—			—			—			—
Net income	$	0.50		$	0.43		$	0.74		$	0.70
Diluted earnings per share:
Income from continuing operations	$	0.49		$	0.43		$	0.74		$	0.69
Income (loss) from discontinued operations		—			—			—			—
Net income	$	0.49		$	0.43		$	0.74		$	0.69
Weighted-average shares outstanding:
Basic		68,296			51,616			65,429			50,872
Diluted		68,735			51,819			65,782			51,174

See accompanying notes.

2

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
	(In thousands)
Net income	$	33,844	$	22,451	$	48,438	$	35,509
Other comprehensive income:
Foreign currency translation gain		46,173		—		16,784		—
Other comprehensive income		46,173		—		16,784		—
Comprehensive income	$	80,017	$	22,451	$	65,222	$	35,509

See accompanying notes.

3

Acadia Healthcare Company, Inc.

Condensed Consolidated Statement of Equity

(Unaudited)

	Common Stock				Additional Paid-in Capital			Other Comprehensive Loss			Retained Earnings (Accumulated Deficit)		Total
	Shares		Amount
Balance at December 31, 2014		59,212	$	592	$	847,301		$	(68,370	)	$	101,442	$	880,965
Common stock issued under stock incentive plans		234		2		(2	)		—			—		—
Common stock withheld for minimum statutory taxes		—		—		(7,826	)		—			—		(7,826	)
Equity-based compensation expense		—		—		9,249			—			—		9,249
Excess tax benefit from equity awards		—		—		6,327			—			—		6,327
Issuance of common stock, net		11,150		112		711,628			—			—		711,740
Other comprehensive loss		—		—		—			16,784			—		16,784
Other		—		—		627			—			—		627
Net income		—		—		—			—			48,438		48,438
Balance at June 30, 2015		70,596	$	706	$	1,567,304		$	(51,586	)	$	149,880	$	1,666,304

See accompanying notes.

4

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Six Months Ended June 30,
	2015			2014
	(In thousands)
Operating activities:
Net income	$	48,438		$	35,509
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization		28,030			11,371
Amortization of debt issuance costs		3,218			1,334
Equity-based compensation expense		9,249			4,170
Deferred income tax expense		24,682			9,097
Income from discontinued operations, net of taxes		(3	)		(31	)
Loss (gain) on foreign currency derivatives		908			(13,735	)
Other		692			25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		(10,442	)		(15,303	)
Other current assets		(13,048	)		(4,792	)
Other assets		(1,218	)		(578	)
Accounts payable and other accrued liabilities		(4,313	)		(1,300	)
Accrued salaries and benefits		(225	)		1,782
Other liabilities		4,619			1,701
Net cash provided by continuing operating activities		90,587			29,250
Net cash provided by (used in) discontinued operating activities		554			(11	)
Net cash provided by operating activities		91,141			29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired		(286,734	)		(10,000	)
Cash paid for capital expenditures		(122,035	)		(43,323	)
Cash paid for real estate acquisitions		(3,428	)		(18,326	)
Settlement of foreign currency derivatives		(908	)		—
Other		(481	)		(439	)
Net cash used in investing activities		(413,586	)		(72,088	)
Financing activities:
Borrowings on long-term debt		875,000			7,500
Borrowings on revolving credit facility		180,000			59,500
Principal payments revolving credit facility		(180,000	)		(113,000	)
Principal payments on long-term debt		(15,875	)		(3,750	)
Repayment of assumed CRC debt		(904,467	)		—
Payment of debt issuance costs		(22,775	)		(5,810	)
Issuance of common stock, net		331,530			374,336
Common stock withheld for minimum statutory taxes, net		(7,826	)		(2,981	)
Excess tax benefit from equity awards		6,327			3,479
Cash paid for contingent consideration		—			(3,250	)
Other		(150	)		—
Net cash provided by financing activities		261,764			316,024
Effect of exchange rate changes on cash		1,213			—
Net (decrease) increase in cash and cash equivalents		(59,468	)		273,175
Cash and cash equivalents at beginning of the period		94,040			4,569
Cash and cash equivalents at end of the period	$	34,572		$	277,744
Effect of acquisitions:
Assets acquired, excluding cash	$	1,636,164		$	10,500
Liabilities assumed		(1,009,944	)		—
Issuance of common stock in connection with acquisition		(380,210	)		—
Deposits paid for acquisitions		40,724			—
Prior year deposits paid for acquisitions		—			(500	)
Cash paid for acquisitions, net of cash acquired	$	286,734		$	10,000

See accompanying notes.

5

Acadia Healthcare Company, Inc.

Notes to Condensed Consolidated Financial Statements

June 30, 2015

(Unaudited)

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico. At June 30, 2015, the Company operated 223 behavioral healthcare facilities with over 9,000 beds in 37 states, the United Kingdom and Puerto Rico.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations, each of which is a direct or indirect wholly-owned subsidiary of the Company. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, all of which are 100% owned. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to prior years to conform to the current year presentation.

2. Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities have a dilutive effect on earnings per share.

6

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2015 and 2014 (in thousands except per share amounts):

	Three Months Ended June 30,					Six Months Ended June 30,
	2015		2014			2015		2014
Numerator:
Basic and diluted earnings per share:
Income from continuing operations	$	33,843	$	22,457		$	48,435	$	35,478
Income (loss) from discontinued operations		1		(6	)		3		31
Net income	$	33,844	$	22,451		$	48,438	$	35,509
Denominator:
Weighted average shares outstanding for basic earnings per share		68,296		51,616			65,429		50,872
Effect of dilutive instruments		439		203			353		302
Shares used in computing diluted earnings per common share		68,735		51,819			65,782		51,174
Basic earnings per share:
Income from continuing operations	$	0.50	$	0.43		$	0.74	$	0.70
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.50	$	0.43		$	0.74	$	0.70
Diluted earnings per share:
Income from continuing operations	$	0.49	$	0.43		$	0.74	$	0.69
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.49	$	0.43		$	0.74	$	0.69

Approximately 0.3 million and 0.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended June 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive. Approximately 0.9 million and 0.5 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the six months ended June 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive.

3. Acquisitions

UK Acquisitions

On June 1, 2015, the Company completed the acquisitions of (i) one facility from Choice for approximately $25.9 million and (ii) 15 facilities from Care UK Limited (“Care UK”) for approximately $88.3 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England.

On April 1, 2015, the Company completed the acquisitions of (i) two facilities from Choice Lifestyles (“Choice”) for approximately $37.5 million, (ii) Pastoral Care Group (“Pastoral”) for approximately $34.2 million and (iii) Mildmay Oaks f/k/a Vista Independent Hospital (“Mildmay Oaks”) for approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England.

QAM

On March 1, 2015, the Company acquired the stock of Quality Addiction Management, Inc. (“QAM”) for total consideration of approximately $54.6 million. QAM operates seven comprehensive treatment centers located in Wisconsin.

7

CRC

On February 11, 2015, the Company completed its acquisition of CRC Health Group, Inc. (“CRC”) for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness of $904.5 million. CRC is a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders. At the acquisition date, CRC operated 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states.

2014 Acquisitions

On December 1, 2014, the Company acquired the assets of Croxton Warwick Lodge (“Croxton”), an inpatient psychiatric facility with 24 beds located in Melton Mowbray, Leicestershire, England, for cash consideration of $15.6 million. On December 31, 2014, the Company completed the acquisition of Skyway House (“Skyway”), a substance abuse facility with 28 beds located in Chico, California, for cash consideration of $0.3 million. On September 3, 2014, the Company completed the acquisition of McCallum Place (“McCallum”), an eating disorder treatment facility with 85 beds offering residential, partial hospitalization and intensive outpatient treatment programs located in St. Louis, Missouri, and Austin, Texas, for total consideration of $37.4 million. On July 1, 2014, the Company acquired Partnerships in Care for cash consideration of $661.7 million, which was net of cash acquired of $12.0 million and the gain on settlement of foreign currency derivatives of $15.3 million. At the acquisition date, Partnerships in Care was the second largest independent provider of inpatient behavioral healthcare services in the United Kingdom, operating 23 inpatient behavioral healthcare facilities with over 1,200 beds. On January 1, 2014, the Company acquired the assets of Pacific Grove Hospital (“Pacific Grove”), an inpatient psychiatric facility with 68 beds located in Riverside, California, for cash consideration of $10.5 million.

Summary of Acquisitions

The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $175.5 million of the goodwill associated with domestic acquisitions completed in 2015 and 2014 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of certain tax matters as well as certain receivables and assumed liabilities of Choice, Care UK, Pastoral, Mildmay Oaks, QAM, CRC and McCallum, the valuation of real property and intangible assets of Choice, Pastoral, Mildmay Oaks, Care UK, QAM and CRC and the valuation of certain tax matters of Partnerships in Care.

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the six months ended June 30, 2015 in connection with the 2015 acquisitions were as follows (in thousands):

	CRC		Other		Total
Cash	$	19,600	$	4,468	$	24,068
Accounts receivable		47,095		6,130		53,225
Prepaid expenses and other current assets		25,522		1,380		26,902
Property and equipment		140,152		138,613		278,765
Goodwill		1,050,620		118,486		1,169,106
Intangible assets		37,000		—		37,000
Deferred tax assets – noncurrent		64,688		—		64,688
Other assets		6,478		—		6,478
Total assets acquired		1,391,155		269,077		1,660,232
Accounts payable		5,301		7,114		12,415
Accrued salaries and benefits		14,860		1,642		16,502
Other accrued expenses		38,703		2,546		41,249
Deferred tax liabilities – noncurrent		—		1,052		1,052
Long-term debt		904,467		—		904,467
Other liabilities		34,248		11		34,259
Total liabilities assumed		997,579		12,365		1,009,944
Net assets acquired	$	393,576	$	256,712	$	650,288

8

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2014 in connection with the 2014 acquisitions were as follows (in thousands):

	Partnerships in Care		Other		Total
Cash	$	11,674	$	—	$	11,674
Accounts receivable		7,684		1,849		9,533
Prepaid expenses and other current assets		8,828		169		8,997
Property and equipment		610,477		27,203		637,680
Goodwill		87,047		32,232		119,279
Intangible assets		651		204		855
Other assets		7,037		3,240		10,277
Total assets acquired		733,398		64,897		798,295
Accounts payable		3,958		93		4,051
Accrued salaries and benefits		10,422		—		10,422
Other accrued expenses		7,166		1,014		8,180
Deferred tax liabilities – noncurrent		15,597		—		15,597
Other liabilities		7,704		—		7,704
Total liabilities assumed		44,847		1,107		45,954
Net assets acquired	$	688,551	$	63,790	$	752,341

Other

The qualitative factors comprising the goodwill acquired in the Pacific Grove, Partnerships in Care, McCallum, Croxton, Skyway, CRC, QAM, Choice, Pastoral, Mildmay Oaks and Care UK acquisitions (collectively the “2014 and 2015 Acquisitions”) include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies.

Transaction-related expenses comprised the following costs for the three and six months ended June 30, 2015 and 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Advisory and financing commitment fees	$	—	$	—	$	10,337	$	—
Legal, accounting and other costs		5,234		3,016		9,054		4,136
Severance and contract termination costs		1,923		—		6,182		459
	$	7,157	$	3,016	$	25,573	$	4,595

Pro Forma Information

The condensed consolidated statements of income for the three and six months ended June 30, 2015 include revenue of $222.1 million and $369.7 million, respectively, and income from continuing operations before income taxes of $37.6 million and $58.1 million, respectively, related to the 2014 and 2015 Acquisitions. The condensed consolidated statements of income for the three and six months ended June 30, 2014 include revenue of $1.6 million and $2.9 million, respectively, and income from continuing operations before income taxes of $0.1 million and loss from continuing operations before income taxes of $0.1 million, respectively, related to acquisitions completed in 2014.

9

The following table provides certain pro forma financial information for the Company as if the 2014 and 2015 Acquisitions occurred as of January 1, 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Revenue	$	461,128	$	431,663	$	901,582	$	841,767
Income from continuing operations, before income taxes	$	51,123	$	32,289	$	39,293	$	31,198

4. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2015		December 31, 2014		June 30, 2015			December 31, 2014
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(1,540	)	$	(1,330	)
Non-compete agreements		1,247		1,247		(1,205	)		(1,155	)
		3,347		3,347		(2,745	)		(2,485	)
Intangible assets not subject to amortization:
Licenses and accreditations		10,318		9,184		—			—
Trade names		37,800		3,000		—			—
Certificates of need		9,794		8,590		—			—
		57,912		20,774		—			—
Total	$	61,259	$	24,121	$	(2,745	)	$	(2,485	)

In connection with the CRC acquisition, the Company acquired license and accreditation intangible assets with a fair value of $1.1 million, trade name intangible assets with a fair value of $34.8 million and certificate of need intangible assets with a fair value of $1.1 million.

Amortization expense related to definite-lived intangible assets was $0.1 million for both the three months ended June 30, 2015 and 2014, respectively, and $0.3 million for both the six months ended June 30, 2015 and 2014, respectively. Estimated amortization expense for the years ending December 31, 2015, 2016, 2017, 2018 and 2019 is $0.5 million, $0.4 million, $0, $0 and $0, respectively. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

5. Property and Equipment

Property and equipment consists of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	June 30, 2015			December 31, 2014
Land	$	201,362		$	132,406
Building and improvements		1,102,767			858,055
Equipment		118,736			73,584
Construction in progress		117,930			66,268
		1,540,795			1,130,313
Less accumulated depreciation		(85,405	)		(60,613	)
Property and equipment, net	$	1,455,390		$	1,069,700

10

6. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2015			December 31, 2014
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans (net of discount of $1,628 and $1,924, respectively)	$	512,497		$	525,576
Senior Secured Term B Loans (net of discount of $2,377)		495,123			—
Senior Secured Revolving Line of Credit		—			—
12.875% Senior Notes due 2018 (net of discount of $967 and $1,080, respectively)		96,533			96,420
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		375,000			—
9.0% and 9.5% Revenue Bonds (net of premium of $1,429 and $1,649, respectively)		24,054			24,274
		1,953,207			1,096,270
Less: current portion		(38,652	)		(26,965	)
Long-term debt	$	1,914,555		$	1,069,305

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (“Amended and Restated Senior Credit Facility”).

On February 13, 2014, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Credit Agreement, to increase the size of the Amended and Restated Senior Credit Facility and extend the maturity date thereof, which resulted in the Company having a revolving line of credit of up to $300.0 million and term loans of $300.0 million. The Fourth Amendment also reduced the interest rates applicable to the Amended and Restated Senior Credit Facility and provided increased flexibility to the Company in terms of the financial and other restrictive covenants. The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.

On June 16, 2014, the Company entered into a Fifth Amendment (the “Fifth Amendment”) to the Amended and Restated Credit Agreement. The Fifth Amendment specifically permitted the Company’s acquisition of Partnerships in Care, gave the Company the ability to incur a tranche of term loan B debt in the future through its incremental credit facility, and modified certain of the restrictive covenants on miscellaneous investments and incurrence of miscellaneous liens. The restrictive covenants on investments in joint ventures and foreign subsidiaries were also amended such that the Company may now invest, in any given fiscal year, up to five percent (5%) of its total assets in both joint ventures and foreign subsidiaries, respectively; provided that the aggregate amount of investments in both joint ventures and foreign subsidiaries, respectively, may not exceed ten percent (10%) of its total assets over the life of the Amended and Restated Senior Credit Facility; provided further that the aggregate amount of investments made in both joint ventures and foreign subsidiaries collectively pursuant to the foregoing may not exceed fifteen percent (15%) of its total assets. Finally, the Fifth Amendment provided increased flexibility to the Company in terms of its financial covenants.

On December 15, 2014, the Company entered into a Sixth Amendment (the “Sixth Amendment”) to our Amended and Restated Credit Agreement. Pursuant to the Sixth Amendment, we incurred $235.0 million of additional term loans. A portion of the additional term loan advance was used to prepay our outstanding revolving loans, and a portion of the additional term loan advance is being held as cash on the consolidated balance sheet. The Sixth Amendment also specifically permitted the acquisition of CRC. In connection with the acquisition of CRC, the Sixth Amendment (i) imposed a temporary reserve on the Company’s revolving credit facility in the amount of $110.0 million in order to preserve such reserved amounts for later borrowings to partially fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) (the reserve is no longer in effect due to the acquisition of CRC), (ii) permitted the incurrence of an additional incremental term loan facility under the Amended and Restated Credit Agreement partially to fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) and (iii) permitted the issuance of additional senior unsecured indebtedness or senior unsecured bridge indebtedness partially to fund the consideration for the acquisition of CRC.

11

On February 6, 2015, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.

On February 11, 2015, the Company entered into a First Incremental Facility Amendment (the “First Incremental Amendment”) to our Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental Term Loan B facility (the “TLB Facility”) that was added to our Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the TLB Facility were used to fund a portion of the purchase price for the acquisition of CRC.

On April 22, 2015, the Company entered into an Eighth Amendment (the “Eighth Amendment”) to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

The Company had $291.1 million of availability under the revolving line of credit as of June 30, 2015. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our outstanding term loan A loans (“TLA Facility”) of $6.7 million for June 30, 2015 to December 31, 2015, $10.0 million for March 31, 2016 to December 31, 2016, $13.4 million for March 31, 2017 to December 31, 2017, and $16.7 million for March 31, 2018 to December 31, 2018, with the remaining principal balance of the TLA Facility due on the maturity date of February 13, 2019. On December 15, 2014, prior to the execution of the Sixth Amendment, the Company prepaid the December 31, 2014 quarterly term loan principal payment of $1.9 million. The Company is required to repay the TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 11, 2022.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 3.25% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 2.25% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at June 30, 2015. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of June 30, 2015, the Pro Rata Facilities bore interest at a rate of LIBOR plus 3.25%. In addition, we are required to pay a commitment fee on undrawn amounts under the revolving line of credit. We paid a commitment fee of 0.50% for undrawn amounts for the period from January 1, 2013 through February 12, 2014 and 0.40% for undrawn amounts for the period from February 13, 2014 through June 30, 2015. Borrowings under the Pro Rata Facilities mature on February 13, 2019.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of June 30, 2015, the Company was in compliance with such covenants.

12.875% Senior Notes due 2018

On November 1, 2011, the Company issued $150.0 million of 12.875% Senior Notes due 2018 (the “12.875% Senior Notes”) at 98.323% of the aggregate principal amount of $150.0 million, a discount of $2.5 million. The notes bear interest at a rate of 12.875% per annum. The Company pays interest on the notes semi-annually, in arrears, on November 1 and May 1 of each year.

The indenture governing the 12.875% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

12

The 12.875% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

On March 12, 2013, the Company redeemed $52.5 million in principal amount of the 12.875% Senior Notes using a portion of the net proceeds of its December 2012 equity offering pursuant to the provision in the indenture permitting an optional redemption with equity proceeds of up to 35% of the principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were redeemed at a redemption price of 112.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date in accordance with the provisions of the indenture governing the 12.875% Senior Notes. As part of the redemption of 35% of the 12.875% Senior Notes, the Company recorded a debt extinguishment charge of $9.4 million, including the premium and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

The indenture governing the 6.125% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 6.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 6.125% Senior Notes at its option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, the Company may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.

The indenture governing the 5.125% Senior Notes contains covenants that limit, among other things, the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

13

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2015.

The indenture governing the 5.625% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.625% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.625% Senior Notes at its option, in whole or part, at any time prior to February 15, 2018, at a price equal to 100% of the principal amount of the 5.625% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. We may redeem the 5.625% Senior Notes, in whole or in part, on or after February 15, 2018, at the redemption prices set forth in the indenture governing the 5.625% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before February 15, 2018, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.625% Senior Notes at a redemption price equal to 105.625% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of June 30, 2015 and December 31, 2014, $2.3 million was recorded within other assets on the balance sheet related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

7. Equity Offerings

On June 17, 2014, the Company completed the offering of 8,881,794 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $44.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.6 million and additional offering-related costs of $0.8 million, were $374.4 million. The Company used the net offering proceeds to fund a portion of the consideration for the acquisition of Partnerships in Care.

On February 11, 2015, the Company completed its acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness.

On May 11, 2015, the Company completed the offering of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $66.50 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.6 million, were $331.5 million. The Company used the net offering proceeds to repay outstanding indebtedness and fund acquisitions.

14

8. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As of June 30, 2015, a maximum of 4,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 1,257,326 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant.

The Company recognized $5.4 million and $2.4 million in equity-based compensation expense for the three months ended June 30, 2015 and 2014, respectively, and $9.2 million and $4.2 million for the six months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was $57.7 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.6 years. As of June 30, 2015, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $2.2 million and $1.0 million for the three months ended June 30, 2015 and 2014, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $3.8 million and $1.7 million for the six months ended June 30, 2015 and 2014, respectively, related to equity-based compensation expense. The actual tax benefit realized from stock options exercised during the three months ended June 30, 2015 and 2014 was $2.0 million and $0.8 million, respectively. The actual tax benefit realized from stock options exercised during the six months ended June 30, 2015 and 2014 was $6.3 million and $3.5 million, respectively.

Stock option activity during 2014 and 2015 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2014		798,809		$	21.93		8.20	$	10,700
Options granted		226,663			49.80		9.25		209
Options exercised		(210,199	)		14.93		N/A		4,994
Options cancelled		(77,851	)		27.85		N/A		N/A
Options outstanding at December 31, 2014		737,422			32.19		8.09		14,512
Options granted		190,900			62.37		9.68		1,148
Options exercised		(49,045	)		23.66		N/A		5,197
Options cancelled		(88,264	)		47.86		N/A		N/A
Options outstanding at June 30, 2015		791,013		$	40.28		8.09	$	23,104
Options exercisable at December 31, 2014		91,947		$	28.87		6.30	$	3,326
Options exercisable at June 30, 2015		153,900		$	34.84		6.60	$	6,941

15

Restricted stock activity during 2014 and 2015 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		461,697		$	24.96
Granted		468,484			48.99
Cancelled		(75,369	)		36.36
Vested		(132,784	)		22.81
Unvested at December 31, 2014		722,028		$	39.77
Granted		480,152			62.08
Cancelled		(55,674	)		49.59
Vested		(107,263	)		32.47
Unvested at June 30, 2015		1,039,243		$	51.03

Restricted stock unit activity during 2014 and 2015 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		95,751		$	23.05
Granted		108,449			50.75
Cancelled		—			—
Vested		(79,087	)		21.81
Unvested at December 31, 2014		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38
Unvested at June 30, 2015		218,084		$	56.97

The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2015 and year ended December 31, 2014:

	June 30, 2015			December 31, 2014
Weighted average grant-date fair value of options	$	24.30		$	17.14
Risk-free interest rate		1.9	%		1.7	%
Expected volatility		33	%		36	%
Expected life (in years)		5.5			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on United States Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

9. Income Taxes

The provision for income taxes for continuing operations for the three months ended June 30, 2015 and 2014 reflects effective tax rates of 31.4% and 39.9%, respectively. The provision for income taxes for continuing operations for the six months ended June 30, 2015 and 2014 reflects effective tax rates of 31.4% and 39.0%, respectively. The decrease in the tax rate for the three and six months ended June 30, 2015 was primarily attributable to the acquisition of Partnerships in Care, which is located in a lower taxing jurisdiction and for which earnings are permanently reinvested.

16

10. Derivatives

The Company entered into foreign currency forward contracts during the three and six months ended June 30, 2015 and 2014 in connection with acquisitions in the United Kingdom. The foreign currency forward contracts limited the economic risk of changes in the foreign exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with the payment of the purchase price in GBP in April 2015 and July 2014. These foreign currency forward contracts did not meet the hedge accounting criteria under Accounting Standards Codification 815, Derivatives and Hedging. As such, losses associated with changes in fair value of $1.0 million and $0.9 million for the three and six months ended June 30, 2015, respectively, have been recorded in the consolidated statements of income. The final fair value of the 2015 foreign currency forward contracts settled during the three and six months ended June 30, 2015. Gains associated with changes in fair value of $13.7 million for the three and six months ended June 30, 2014 have been recorded in the consolidated statements of income. The final fair value of the 2014 foreign currency forward contracts settled on July 1, 2014 for $15.3 million in connection with the acquisition of Partnerships in Care.

11. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of June 30, 2015 and December 31, 2014 were as follows (in thousands):

	Carrying Amount				Fair Value
	June 30, 2015		December 31, 2014		June 30, 2015		December 31, 2014
Amended and Restated Senior Credit Facility	$	1,007,620	$	525,576	$	1,007,620	$	525,576
12.875% Senior Notes due 2018	$	96,533	$	96,420	$	106,519	$	109,688
6.125% Senior Notes due 2021	$	150,000	$	150,000	$	154,500	$	153,000
5.125% Senior Notes due 2022	$	300,000	$	300,000	$	297,750	$	295,500
5.625% Senior Notes due 2023	$	375,000		—	$	379,688		—
9.0% and 9.5% Revenue Bonds	$	24,054	$	24,274	$	24,054	$	24,274
Contingent consideration liabilities	$	3,000	$	3,000	$	3,000	$	3,000

The Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate. Significant increases with respect to assumptions as to future earnings and probabilities of achieving such future earnings would result in higher fair value measurement while an increase in the discount rate would result in a lower fair value measurement. During the six months ended June 30, 2014, the Company changed its projections of the timing of future payments of the contingent consideration liability related to the acquisition of The Pavilion at Healthpark LLC (“Park Royal”). This change resulted in a $0.5 million increase in the fair value of the contingent consideration liability, which was recorded in transaction-related expenses in the consolidated statements of income. During the year ended December 31, 2014, the Company paid $5.0 million of the estimated $7.0 million Park Royal contingent consideration liability as a result of the facility achieving certain earnings targets. In addition to the Park Royal contingent consideration liability, the Company may make an earn-out payment of up to $6.0 million to the former owners of McCallum, contingent upon achievement by McCallum of certain operating performance targets for the one-year period ending December 31, 2015.

12. Commitments and Contingencies

The Company is, from time to time, subject to various claims and legal actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

17

13. Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At June 30, 2015, the U.S. Facilities included 178 behavioral healthcare facilities with approximately 7,200 beds in 37 states and Puerto Rico, and the U.K. Facilities included 45 behavioral healthcare facilities with approximately 1,800 beds in the United Kingdom.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Revenue:
U.S. Facilities	$	366,886		$	212,834		$	657,393		$	413,398
U.K. Facilities		84,927			—			158,242			—
Corporate and Other		1,847			969			3,808			1,823
	$	453,660		$	213,803		$	819,443		$	415,221
Segment EBITDA (1):
U.S. Facilities	$	102,342		$	53,031		$	178,706		$	100,563
U.K. Facilities		20,371			—			39,182			—
Corporate and Other		(16,910	)		(8,317	)		(33,373	)		(16,567	)
	$	105,803		$	44,714		$	184,515		$	83,996

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Segment EBITDA (1)	$	105,803		$	44,714		$	184,515		$	83,996
Plus (less):
Equity-based compensation expense		(5,355	)		(2,406	)		(9,249	)		(4,170	)
(Loss) gain on foreign currency derivatives		(961	)		13,735			(908	)		13,735
Transaction-related expenses		(7,157	)		(3,016	)		(25,573	)		(4,595	)
Interest expense, net		(28,049	)		(9,730	)		(50,195	)		(19,437	)
Depreciation and amortization		(14,926	)		(5,935	)		(28,030	)		(11,371	)
Income from continuing operations before income taxes	$	49,355		$	37,362		$	70,560		$	58,158

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2015	$	693,945	$	109,041		$	—	$	802,986
Increase from 2015 acquisitions		1,103,813		65,293			—		1,169,106
Foreign currency translation		—		6,972			—		6,972
Purchase price allocation and other		281		(33,317	)		—		(33,036	)
Balance at June 30, 2015	$	1,798,039	$	147,989		$	—	$	1,946,028

18

	June 30, 2015		December 31, 2014
Assets (2):
U.S. Facilities	$	2,729,896	$	1,327,563
U.K. Facilities		944,033		726,693
Corporate and Other		252,456		169,334
	$	3,926,385	$	2,223,590

(1) Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, gain/loss on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2) Assets include property and equipment for the U.S. Facilities of $671.2 million, U.K. Facilities of $754.2 million and corporate and other of $30.0 million at June 30, 2015. Assets include property and equipment for the U.S. Facilities of $478.1 million, U.K. Facilities of $578.6 million and corporate and other of $13.0 million at December 31, 2014.

14. Recently Issued Accounting Standards

In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-03, “Interest-Imputation of Interest (Subtopic 835-30)” (“ASU 2015-05”). ASU 2015-03 simplifies the presentation of debt issuance costs by requiring debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, and the new guidance should be applied retrospectively. Management is evaluating the impact of ASU 2015-03 on the Company’s consolidated financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09’s core principal is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Additionally, ASU 2014-09 would permit both public and nonpublic organizations to adopt the new revenue standard early, but not before the original public organization effective date (that is, annual periods beginning after December 15, 2016). Management is evaluating the impact of ASU 2014-09 on the Company’s consolidated financial statements.

15. Subsequent Events

On July 1, 2015, the Company completed the acquisition of (i) the assets of Belmont Behavioral Health, an inpatient psychiatric facility with 147 beds located in Philadelphia, Pennsylvania for cash consideration of approximately $40.0 million which consists of $35.0 million base purchase price and an estimated working capital settlement of $5.0 million, and (ii) The Manor Clinic, a substance abuse facility with 15 beds located in England, for cash consideration of approximately $5.9 million.

19

16. Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes and 5.625% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of June 30, 2015 and December 31, 2014, and for the three and six months ended June 30, 2015 and 2014. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2015

(In thousands) 

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	17,179	$	17,393	$	—		$	34,572
Accounts receivable, net		—		160,179		22,136		—			182,315
Deferred tax assets		—		36,502		2,191		—			38,693
Other current assets		—		62,295		8,030		—			70,325
Total current assets		—		276,155		49,750		—			325,905
Property and equipment, net		—		656,262		799,128		—			1,455,390
Goodwill		—		1,700,705		245,323		—			1,946,028
Intangible assets, net		—		55,928		2,586		—			58,514
Deferred tax assets – noncurrent		5,361		16,239		12,366		—			33,966
Investment in subsidiaries		1,332,308		—		—		(1,332,308	)		—
Other assets		389,676		65,957		2,322		(351,373	)		106,582
Total assets	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385
Current liabilities:
Current portion of long-term debt	$	38,437	$	—	$	215	$	—		$	38,652
Accounts payable		—		44,985		13,729		—			58,714
Accrued salaries and benefits		—		65,040		12,505		—			77,545
Other accrued liabilities		22,604		27,543		18,050		—			68,197
Total current liabilities		61,041		137,568		44,499		—			243,108
Long-term debt		—		1,890,716		375,212		(351,373	)		1,914,555
Deferred tax liabilities – noncurrent		—		—		20,200		—			20,200
Other liabilities		—		72,329		9,889		—			82,218
Total liabilities		61,041		2,100,613		449,800		(351,373	)		2,260,081
Total equity		1,666,304		670,633		661,675		(1,332,308	)		1,666,304
Total liabilities and equity	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385

20

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2014

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	76,685	$	17,355	$	—		$	94,040
Accounts receivable, net		—		100,797		17,581		—			118,378
Deferred tax assets		—		18,395		1,760		—			20,155
Other current assets		—		36,049		5,521		—			41,570
Total current assets		—		231,926		42,217		—			274,143
Property and equipment, net		—		451,943		617,757		—			1,069,700
Goodwill		—		596,611		206,375		—			802,986
Intangible assets, net		—		19,057		2,579		—			21,636
Deferred tax assets – noncurrent		4,563		—		14,244		(5,666	)		13,141
Investment in subsidiaries		1,759,337		—		—		(1,759,337	)		—
Other assets		202,708		18,727		2,323		(181,774	)		41,984
Total assets	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590
Current liabilities:
Current portion of long-term debt	$	26,750	$	—	$	215	$	—		$	26,965
Accounts payable		—		39,486		9,210		—			48,696
Accrued salaries and benefits		—		47,597		11,720		—			59,317
Other accrued liabilities		13,647		7,688		9,621		—			30,956
Total current liabilities		40,397		94,771		30,766		—			165,934
Long-term debt		1,045,246		—		205,833		(181,774	)		1,069,305
Deferred tax liabilities – noncurrent		—		21,027		48,519		(5,666	)		63,880
Other liabilities		—		33,321		10,185		—			43,506
Total liabilities		1,085,643		149,119		295,303		(187,440	)		1,342,625
Total equity		880,965		1,169,145		590,192		(1,759,337	)		880,965
Total liabilities and equity	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

21

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	363,851		$	97,947		$	—		$	461,798
Provision for doubtful accounts		—			(7,566	)		(572	)		—			(8,138	)
Revenue		—			356,285			97,375			—			453,660
Salaries, wages and benefits		5,355			183,490			54,457			—			243,302
Professional fees		—			22,579			7,450			—			30,029
Supplies		—			16,929			3,613			—			20,542
Rents and leases		—			7,402			809			—			8,211
Other operating expenses		—			43,145			7,983			—			51,128
Depreciation and amortization		—			10,551			4,375			—			14,926
Interest expense, net		18,106			5,882			4,061			—			28,049
Loss on foreign currency derivatives		961			—			—			—			961
Transaction-related expenses		—			2,946			4,211			—			7,157
Total expenses		24,422			292,924			86,959			—			404,305
(Loss) income from continuing operations before income taxes		(24,422	)		63,361			10,416			—			49,355
Equity in earnings of subsidiaries		50,281			—			—			(50,281	)		—
(Benefit from) provision for income taxes		(7,985	)		20,734			2,763			—			15,512
Income (loss) from continuing operations		33,844			42,627			7,653			(50,281	)		33,843
Income from discontinued operations, net of income taxes		—			1			—			—			1
Net income (loss)	$	33,844		$	42,628		$	7,653		$	(50,281	)	$	33,844
Other comprehensive income:
Foreign currency translation gain		—			—			46,173			—			46,173
Other comprehensive income		—			—			46,173			—			46,173
Comprehensive income (loss)	$	33,844		$	42,628		$	53,826		$	(50,281	)	$	80,017

22

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	207,143		$	13,521		$	—		$	220,664
Provision for doubtful accounts		—			(5,954	)		(907	)		—			(6,861	)
Revenue		—			201,189			12,614			—			213,803
Salaries, wages and benefits		2,406			114,976			5,091			—			122,473
Professional fees		—			9,691			1,200			—			10,891
Supplies		—			9,967			629			—			10,596
Rents and leases		—			2,613			276			—			2,889
Other operating expenses		—			22,522			2,124			—			24,646
Depreciation and amortization		—			5,581			354			—			5,935
Interest expense, net		9,202			—			528			—			9,730
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			3,016			—			—			3,016
Total expenses		(2,127	)		168,366			10,202			—			176,441
Income from continuing operations before income taxes		2,127			32,823			2,412			—			37,362
Equity in earnings of subsidiaries		20,972			—			—			(20,972	)		—
Provision for income taxes		648			13,315			942			—			14,905
Income (loss) from continuing operations		22,451			19,508			1,470			(20,972	)		22,457
Loss from discontinued operations, net of income taxes		—			(6	)		—			—			(6	)
Net income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451
Comprehensive income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451

23

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	651,616		$	184,340		$	—		$	835,956
Provision for doubtful accounts		—			(14,985	)		(1,528	)		—			(16,513	)
Revenue		—			636,631			182,812			—			819,443
Salaries, wages and benefits		9,249			339,189			100,735			—			449,173
Professional fees		—			39,064			13,392			—			52,456
Supplies		—			29,938			6,858			—			36,796
Rents and leases		—			12,519			1,578			—			14,097
Other operating expenses		—			75,392			16,263			—			91,655
Depreciation and amortization		—			19,262			8,768			—			28,030
Interest expense, net		31,054			11,603			7,538			—			50,195
Loss on foreign currency derivatives		908			—			—			—			908
Transaction-related expenses		—			21,362			4,211			—			25,573
Total expenses		41,211			548,329			159,343			—			748,883
(Loss) income from continuing operations before income taxes		(41,211	)		88,302			23,469			—			70,560
Equity in earnings of subsidiaries		76,268			—			—			(76,268	)		—
(Benefit from) provision for income taxes		(13,381	)		29,251			6,255			—			22,125
Income (loss) from continuing operations		48,438			59,051			17,214			(76,268	)		48,435
Income from discontinued operations, net of income taxes		—			3			—			—			3
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Other comprehensive income:
Foreign currency translation gain		—			—			16,784			—			16,784
Other comprehensive income		—			—			16,784			—			16,784
Comprehensive income (loss)	$	48,438		$	59,054		$	33,998		$	(76,268	)	$	65,222

24

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	400,425		$	26,358		$	—		$	426,783
Provision for doubtful accounts		—			(10,464	)		(1,098	)		—			(11,562	)
Revenue		—			389,961			25,260			—			415,221
Salaries, wages and benefits		4,170			225,629			10,249			—			240,048
Professional fees		—			18,944			2,329			—			21,273
Supplies		—			19,353			1,307			—			20,660
Rents and leases		—			5,108			550			—			5,658
Other operating expenses		—			43,600			4,156			—			47,756
Depreciation and amortization		—			10,666			705			—			11,371
Interest expense, net		18,313			—			1,124			—			19,437
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			4,595			—			—			4,595
Total expenses		8,748			327,895			20,420			—			357,063
(Loss) income from continuing operations before income taxes		(8,748	)		62,066			4,840			—			58,158
Equity in earnings of subsidiaries		40,839			—			—			(40,839	)		—
(Benefit from) provision for income taxes		(3,418	)		24,249			1,849			—			22,680
Income (loss) from continuing operations		35,509			37,817			2,991			(40,839	)		35,478
Income from discontinued operations, net of income taxes		—			31			—			—			31
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Comprehensive income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509

25

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(76,268	)		—			—			76,268			—
Depreciation and amortization		—			19,262			8,768			—			28,030
Amortization of debt issuance costs		—			3,438			(220	)		—			3,218
Equity-based compensation expense		9,249			—			—			—			9,249
Deferred income tax (benefit) expense		(798	)		22,964			2,516			—			24,682
Loss from discontinued operations, net of taxes		—			(3	)		—			—			(3	)
Loss (gain) on foreign currency derivatives		908			—			—			—			908
Other		—			662			30			—			692
Change in operating assets and liabilities, net of effect of acquisitions:											—
Accounts receivable, net		—			(11,409	)		967			—			(10,442	)
Other current assets		—			(12,026	)		(1,022	)		—			(13,048	)
Other assets		(300	)		(1,220	)		2			300			(1,218	)
Accounts payable and other accrued liabilities		—			5,991			(10,304	)		—			(4,313	)
Accrued salaries and benefits		—			791			(1,016	)		—			(225	)
Other liabilities		—			5,442			(823	)		—			4,619
Net cash (used in) provided by continuing operating activities		(18,771	)		92,946			16,112			300			90,587
Net cash provided by discontinued operating activities		—			554			—			—			554
Net cash (used in) provided by operating activities		(18,771	)		93,500			16,112			300			91,141
Investing activities:											—
Cash paid for acquisitions, net of cash acquired		—			(89,041	)		(197,693	)		—			(286,734	)
Cash paid for capital expenditures		—			(62,101	)		(59,934	)		—			(122,035	)
Cash paid for real estate acquisitions		—			(3,428	)		—			—			(3,428	)
Settlement of foreign currency derivatives		—			(908	)		—			—			(908	)
Other		—			(481	)		—			—			(481	)
Net cash used in investing activities		—			(155,959	)		(257,627	)		—			(413,586	)
Financing activities:											—
Borrowings on long-term debt		875,000			—			—			—			875,000
Borrowings on revolving credit facility		180,000			—			—			—			180,000
Principal payments on revolving credit facility		(180,000	)		—			—			—			(180,000	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Principal payments on long-term debt		(15,875	)		—			(300	)		300			(15,875	)
Payment of debt issuance costs		—			(22,775	)		—			—			(22,775	)
Issuance of Common Stock		—			331,530			—			—			331,530
Common stock withheld for minimum statutory taxes, net		—			(7,826	)		—			—			(7,826	)
Excess tax benefit from equity awards		—			6,327			—			—			6,327
Other		—			(150	)		—			—			(150	)
Cash provided by (used in) intercompany activity		64,113			(305,366	)		241,853			(600	)		—
Net cash provided by (used in) financing activities		18,771			1,740			241,553			(300	)		261,764
Effect of exchange rate changes on cash		—			1,213			—			—			1,213
Net (decrease) increase in cash and cash equivalents		—			(59,506	)		38			—			(59,468	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040
Cash and cash equivalents at end of the period	$	—		$	17,179		$	17,393		$	—		$	34,572

26

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(40,839	)		—			—			40,839			—
Depreciation and amortization		—			10,666			705			—			11,371
Amortization of debt issuance costs		1,560			—			(226	)		—			1,334
Equity-based compensation expense		4,170			—			—			—			4,170
Deferred income tax expense		5,585			3,105			407			—			9,097
Income from discontinued operations, net of taxes		—			(31	)		—			—			(31	)
Gain on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Other		—			25			—			—			25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(16,670	)		1,367			—			(15,303	)
Other current assets		—			(5,033	)		241			—			(4,792	)
Other assets		165			(578	)		—			(165	)		(578	)
Accounts payable and other accrued liabilities		—			(1,584	)		284			—			(1,300	)
Accrued salaries and benefits		—			1,701			81			—			1,782
Other liabilities		—			1,701			—			—			1,701
Net cash (used in) provided by continuing operating activities		(7,585	)		31,150			5,850			(165	)		29,250
Net cash used in discontinued operating activities		—			(11	)		—			—			(11	)
Net cash (used in) provided by operating activities		(7,585	)		31,139			5,850			(165	)		29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(10,000	)		—			—			(10,000	)
Cash paid for capital expenditures		—			(39,782	)		(3,541	)		—			(43,323	)
Cash paid for real estate acquisitions		—			(18,326	)		—			—			(18,326	)
Other		—			(439	)		—			—			(439	)
Net cash used in investing activities		—			(68,547	)		(3,541	)		—			(72,088	)
Financing activities:
Borrowings on long-term debt		7,500			—			—			—			7,500
Borrowings on revolving credit facility		59,500			—			—			—			59,500
Principal payments on revolving credit facility		(113,000	)		—			—			—			(113,000	)
Principal payments on long-term debt		(3,750	)		—			(165	)		165			(3,750	)
Payment of debt issuance costs		(5,810	)		—			—			—			(5,810	)
Issuance of common stock, net		374,336			—			—			—			374,336
Common stock withheld for minimum statutory taxes, net		(2,981	)		—			—			—			(2,981	)
Excess tax benefit from equity awards		3,479			—			—			—			3,479
Cash paid for contingent consideration		—			(3,250	)		—			—			(3,250	)
Cash (used in) provided by intercompany activity		(311,689	)		315,175			(5,411	)		1,925			—
Net cash provided by (used in) financing activities		7,585			311,925			(5,576	)		2,090			316,024
Net increase (decrease) in cash and cash equivalents		—			274,517			(3,267	)		1,925			273,175
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569
Cash and cash equivalents at end of the period	$	—		$	274,517		$	3,227		$	—		$	277,744

27

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “would,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contained are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to:

• our significant indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt;

• difficulties in successfully integrating the operations of acquired facilities, including those acquired in the CRC and Partnerships in Care acquisitions, or realizing the potential benefits and synergies of our acquisitions;

• our ability to implement our business strategies in the United Kingdom and adapt to the regulatory and business environment in the United Kingdom;

• the impact of payments received from the government and third-party payors on our revenues and results of operations including the significant dependence of the Partnerships in Care facilities on payments received from the National Health Service in the United Kingdom (“NHS”);

• the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations;

• our future cash flow and earnings;

• our restrictive covenants, which may restrict our business and financing activities;

• our ability to make payments on our financing arrangements;

• the impact of the economic and employment conditions in the United States and the United Kingdom on our business and future results of operations;

• compliance with laws and government regulations;

• the impact of claims brought against our facilities;

• the impact of governmental investigations, regulatory actions and whistleblower lawsuits;

• the impact of healthcare reform in the United States and abroad;

• the impact of our highly competitive industry on patient volumes;

• our ability to recruit and retain quality psychiatrists and other physicians;

• the impact of competition for staffing on our labor costs and profitability;

• our dependence on key management personnel, key executives and local facility management personnel;

• our acquisition strategy, which exposes us to a variety of operational and financial risks, as well as legal and regulatory risks (e.g., exposure to the new regulatory regimes such as the United Kingdom for Partnerships in Care and various investigations relating to CRC);

• the impact of state efforts to regulate the construction or expansion of healthcare facilities (including those from CRC and Partnerships in Care) on our ability to operate and expand our operations;

• our potential inability to extend leases at expiration;

• the impact of controls designed to reduce inpatient services on our revenues;

• the impact of different interpretations of accounting principles on our results of operations or financial condition;

• the impact of environmental, health and safety laws and regulations, especially in states where we have concentrated operations;

• the impact of an increase in uninsured and underinsured patients or the deterioration in the collectability of the accounts of such patients on our results of operations;

• the risk of a cyber-security incident and any resulting violation of laws and regulations regarding information privacy or other negative impact;

• the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions;

28

• the impact of a change in the mix of our earnings, and changes in tax rates and laws generally;

• failure to maintain effective internal control over financial reporting;

• the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities;

• the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts on our ability to obtain patients;

• the impact of fluctuations in foreign exchange rates; and

• those risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date of this Quarterly Report on Form 10-Q. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Overview

Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At June 30, 2015, we operated 223 behavioral healthcare facilities with over 9,000 beds in 37 states, the United Kingdom and Puerto Rico. During the six months ended June 30, 2015, we acquired 144 facilities and added approximately 250 new beds, including one de novo facility. For the year ending December 31, 2015, we expect to add approximately 500 total beds to facilities we owned as of December 31, 2014.

We are the leading publicly traded pure-play provider of behavioral healthcare services, with operations in the United States and the United Kingdom. Management believes that the Company’s recent acquisitions position the Company as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume of out-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count.

Acquisitions

On February 11, 2015, we completed the acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, we issued 5,975,326 shares of our common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness. CRC is a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders. At the acquisition date, CRC operated 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states.

On March 1, 2015, we acquired the stock of QAM for total consideration of approximately $54.6 million. QAM operates seven comprehensive treatment centers located in Wisconsin.

On April 1, 2015, we completed the acquisitions of (i) two facilities from Choice for approximately $37.5 million, (ii) Pastoral for approximately $34.2 million and (iii) Mildmay Oaks for approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England.

On June 1, 2015, we completed the acquisitions of (i) one facility from Choice for approximately $25.9 million and (ii) 15 facilities from Care UK for approximately $88.3 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England.

Revenue

Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal

29

government under the Medicare program administered by CMS; (iv) NHS in the United Kingdom; and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.

The following table presents revenue by payor type and as a percentage of revenue before provision for doubtful accounts for the three and six months ended June 30, 2015 and 2014 (dollars in thousands):

	Three Months Ended June 30,												Six Months Ended June 30,
	2015						2014						2015						2014
	Amount			%			Amount			%			Amount			%			Amount			%
Commercial	$	108,059			23.4	%	$	58,429			26.5	%	$	191,533			22.9	%	$	114,614			26.8	%
Medicare		51,987			11.3	%		48,581			22.0	%		101,132			12.1	%		94,267			22.1	%
Medicaid		154,204			33.4	%		101,546			46.0	%		280,528			33.6	%		193,316			45.3	%
NHS		83,069			18.0	%		—			—	%		155,635			18.6	%		—			—	%
Self-Pay		50,559			10.9	%		6,207			2.8	%		80,287			9.6	%		13,214			3.1	%
Other		13,920			3.0	%		5,901			2.7	%		26,841			3.2	%		11,372			2.7	%
Revenue before provision for doubtful accounts		461,798			100.0	%		220,664			100.0	%		835,956			100.0	%		426,783			100.0	%
Provision for doubtful accounts		(8,138	)					(6,861	)					(16,513	)					(11,562	)
Revenue	$	453,660					$	213,803					$	819,443					$	415,221

The following tables present a summary of our aging of accounts receivable as of June 30, 2015 and December 31, 2014:

June 30, 2015

	Current			30-90			90-150			>150			Total
Commercial		19.0	%		8.2	%		3.1	%		1.9	%		32.2	%
Medicare		12.3	%		1.9	%		1.0	%		2.0	%		17.2	%
Medicaid		24.3	%		7.1	%		2.7	%		1.9	%		36.0	%
NHS		1.9	%		2.4	%		—	%		—	%		4.3	%
Self-Pay		1.3	%		2.0	%		2.1	%		3.7	%		9.1	%
Other		0.5	%		0.4	%		0.1	%		0.2	%		1.2	%
Total		59.3	%		22.0	%		9.0	%		9.7	%		100.0	%
December 31, 2014
	Current			30-90			90-150			>150			Total
Commercial		14.5	%		6.7	%		2.6	%		3.1	%		26.9	%
Medicare		15.8	%		3.4	%		1.7	%		3.7	%		24.6	%
Medicaid		22.2	%		4.9	%		2.3	%		2.8	%		32.2	%
NHS		2.1	%		1.8	%		0.1	%		—	%		4.0	%
Self-Pay		1.1	%		1.8	%		2.2	%		6.2	%		11.3	%
Other		0.3	%		0.2	%		0.2	%		0.3	%		1.0	%
Total		56.0	%		18.8	%		9.1	%		16.1	%		100.0	%

30

Results of Operations

The following table illustrates our consolidated results of operations from continuing operations for the respective periods shown (dollars in thousands):

	Three Months Ended June 30,												Six Months Ended June 30,
	2015						2014						2015						2014
	Amount			%			Amount			%			Amount			%			Amount			%
Revenue before provision for doubtful accounts	$	461,798					$	220,664					$	835,956					$	426,783
Provision for doubtful accounts		(8,138	)					(6,861	)					(16,513	)					(11,562	)
Revenue		453,660			100.0	%		213,803			100.0	%		819,443			100.0	%		415,221			100.0	%
Salaries, wages and benefits		243,302			53.6	%		122,473			57.3	%		449,173			54.8	%		240,048			57.8	%
Professional fees		30,029			6.6	%		10,891			5.1	%		52,456			6.4	%		21,273			5.1	%
Supplies		20,542			4.5	%		10,596			5.0	%		36,796			4.5	%		20,660			5.0	%
Rents and leases		8,211			1.8	%		2,889			1.3	%		14,097			1.7	%		5,658			1.4	%
Other operating expenses		51,128			11.3	%		24,646			11.5	%		91,655			11.2	%		47,756			11.5	%
Depreciation and amortization		14,926			3.3	%		5,935			2.8	%		28,030			3.4	%		11,371			2.7	%
Interest expense		28,049			6.2	%		9,730			4.5	%		50,195			6.1	%		19,437			4.7	%
Loss (gain) on foreign currency derivatives		961			0.2	%		(13,735	)		(6.4	)%		908			0.1	%		(13,735	)		(3.3	)%
Transaction-related expenses		7,157			1.6	%		3,016			1.4	%		25,573			3.1	%		4,595			1.1	%
Total expenses		404,305			89.1	%		176,441			82.5	%		748,883			91.3	%		357,063			86.0	%
Income from continuing operations before income taxes		49,355			10.9	%		37,362			17.5	%		70,560			8.6	%		58,158			14.0	%
Provision for income taxes		15,512			3.4	%		14,905			7.0	%		22,125			2.7	%		22,680			5.5	%
Income from continuing operations	$	33,843			7.5	%	$	22,457			10.5	%	$	48,435			5.9	%	$	35,478			8.5	%

Three months ended June 30, 2015 compared to the three months ended June 30, 2014

Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $241.1 million, or 109.3%, to $461.8 million for the three months ended June 30, 2015 from $220.7 million for the three months ended June 30, 2014. The increase related primarily to revenue generated during the three months ended June 30, 2015 from the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility revenue before provision for doubtful accounts increased by $17.9 million, or 8.3%, for the three months ended June 30, 2015 compared to the three months ended June 30, 2014, resulting from same-facility growth in patient days of 7.4% and an increase in same-facility revenue per day of 1.5%. Consistent with the same-facility patient day growth in 2014, the growth in same-facility patient days for the three months ended June 30, 2015 compared to the three months ended June 30, 2014 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

Provision for doubtful accounts. The provision for doubtful accounts was $8.1 million for the three months ended June 30, 2015, or 1.8% of revenue before provision for doubtful accounts, compared to $6.9 million for the three months ended June 30, 2014, or 3.1% of revenue before provision for doubtful accounts.

Salaries, wages and benefits. Salaries, wages and benefits (“SWB”) expense was $243.3 million for the three months ended June 30, 2015 compared to $122.5 million for the three months ended June 30, 2014, an increase of $120.8 million. SWB expense included $5.4 million and $2.4 million of equity-based compensation expense for the three months ended June 30, 2015 and 2014, respectively. Excluding equity-based compensation expense, SWB expense was $237.9 million, or 52.5% of revenue, for the three months ended June 30, 2015, compared to $120.1 million, or 56.2% of revenue, for the three months ended June 30, 2014. The $117.8 million increase in SWB expense, excluding equity-based compensation expense, was primarily attributable to SWB expense incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility SWB expense was $116.0 million for the three months ended June 30, 2015, or 50.7% of revenue, compared to $111.2 million for the three months ended June 30, 2014, or 53.0% of revenue.

Professional fees. Professional fees were $30.0 million for the three months ended June 30, 2015, or 6.6% of revenue, compared to $10.9 million for the three months ended June 30, 2014, or 5.1% of revenue. The $19.1 million increase was primarily attributable to professional fees incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility professional fees were $11.1 million for the three months ended June 30, 2015, or 4.9% of revenue, compared to $9.5 million, for the three months ended June 30, 2014, or 4.5% of revenue.

31

Supplies. Supplies expense was $20.5 million for the three months ended June 30, 2015, or 4.5% of revenue, compared to $10.6 million for the three months ended June 30, 2014, or 5.0% of revenue. The $9.9 million increase was primarily attributable to supplies expense incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility supplies expense was $11.0 million for the three months ended June 30, 2015, or 4.8% of revenue, compared to $10.4 million for the three months ended June 30, 2014, or 5.0% of revenue.

Rents and leases. Rents and leases were $8.2 million for the three months ended June 30, 2015, or 1.8% of revenue, compared to $2.9 million for the three months ended June 30, 2014, or 1.3% of revenue. The $5.3 million increase was primarily attributable to rents and leases incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility rents and leases were $2.5 million for the three months ended June 30, 2015, or 1.1% of revenue, compared to $2.8 million for the three months ended June 30, 2014, or 1.3% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $51.1 million for the three months ended June 30, 2015, or 11.3% of revenue, compared to $24.6 million for the three months ended June 30, 2014, or 11.5% of revenue. The $26.5 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility other operating expenses were $28.3 million for the three months ended June 30, 2015, or 12.4% of revenue, compared to $23.7 million for the three months ended June 30, 2014, or 11.3% of revenue.

Depreciation and amortization. Depreciation and amortization expense was $14.9 million for the three months ended June 30, 2015, or 3.3% of revenue, compared to $5.9 million for the three months ended June 30, 2014, or 2.8% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2014 and 2015 and real estate acquired as part of the 2014 and 2015 Acquisitions, particularly the acquisition of Partnerships in Care.

Interest expense. Interest expense was $28.0 million for the three months ended June 30, 2015 compared to $9.7 million for the three months ended June 30, 2014. The increase in interest expense was primarily a result of borrowings under the Amended and Restated Senior Credit Facility, the issuance of the 5.125% Senior Notes on July 1, 2014 and the issuance of the 5.625% Senior Notes on February 11, 2015.

Loss (gain) on foreign currency derivatives. In connection with acquisitions in the United Kingdom, the Company entered into foreign currency forward contracts in May 2015 in order to fix the exchange rate applicable to the payment of acquisition purchase prices in June 2015. Unfavorable exchange rate changes resulted in a decrease in the fair value of the forward contracts and a loss on foreign currency derivatives of $1.0 million for the three months ended June 30, 2015, compared to gain of $13.7 million for the three months ended June 30, 2014 related to the acquisition of Partnerships in Care on July 1, 2014.

Transaction-related expenses. Transaction-related expenses were $7.2 million for the three months ended June 30, 2015 compared to $3.0 million for the three months ended June 30, 2014. Transaction-related expenses represent costs incurred in the respective periods, primarily related to the 2014 and 2015 Acquisitions, as summarized below (in thousands):

	Three Months Ended June 30,
	2015		2014
Legal, accounting and other costs	$	5,234	$	3,016
Severance and contract termination costs		1,923		—
	$	7,157	$	3,016

Provision for income taxes. For the three months ended June 30, 2015, the provision for income taxes was $15.5 million, reflecting an effective tax rate of 31.4%, compared to $14.9 million, reflecting an effective tax rate of 39.9%, for the three months ended June 30, 2014. The decrease in the tax rate for the three months ended June 30, 2015 was primarily attributable to the acquisition of Partnerships in Care, which is located in a lower taxing jurisdiction and for which earnings are permanently reinvested.

Six months ended June 30, 2015 compared to the six months ended June 30, 2014

Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $409.2 million, or 95.9%, to $836.0 million for the six months ended June 30, 2015 from $426.8 million for the six months ended June 30, 2014. The increase related primarily to revenue generated during the six months ended June 30, 2015 from the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility revenue before provision for doubtful accounts increased $38.4 million, or 9.2%, for the six months ended June 30, 2015 compared to the six months ended June 30, 2014, resulting from same-facility growth in patient days of 8.9% and an increase in same-facility revenue per day of 0.2%. Consistent with the same-facility patient day growth in 2014, the growth in same-facility patient days for the six months ended June 30, 2015 compared to the six months ended June 30, 2014 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

32

Provision for doubtful accounts. The provision for doubtful accounts was $16.5 million for the six months ended June 30, 2015, or 2.0% of revenue before provision for doubtful accounts, compared to $11.6 million for the six months ended June 30, 2014, or 2.7% of revenue before provision for doubtful accounts.

Salaries, wages and benefits. SWB expense was $449.2 million for the six months ended June 30, 2015 compared to $240.0 million for the six months ended June 30, 2014, an increase of $209.2 million. SWB expense included $9.3 million and $4.2 million of equity-based compensation expense for the six months ended June 30, 2015 and 2014, respectively. Excluding equity-based compensation expense, SWB expense was $439.9 million, or 53.7% of revenue, for the six months ended June 30, 2015, compared to $235.8 million, or 56.8% of revenue, for the six months ended June 30, 2014. The $204.1 million increase in SWB expense, excluding equity-based compensation expense, was primarily attributable to SWB expense incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility SWB expense was $230.5 million for the six months ended June 30, 2015, or 51.9% of revenue, compared to $218.0 million for the six months ended June 30, 2014, or 53.5% of revenue.

Professional fees. Professional fees were $52.5 million for the six months ended June 30, 2015, or 6.4% of revenue, compared to $21.3 million for the six months ended June 30, 2014, or 5.1% of revenue. The $31.2 million increase was primarily attributable to professional fees incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility professional fees were $21.3 million for the six months ended June 30, 2015, or 4.8% of revenue, compared to $18.5 million, for the six months ended June 30, 2014, or 4.5% of revenue.

Supplies. Supplies expense was $36.8 million for the six months ended June 30, 2015, or 4.5% of revenue, compared to $20.7 million for the six months ended June 30, 2014, or 5.0% of revenue. The $16.1 million increase was primarily attributable to supplies expense incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility supplies expense was $21.1 million for the six months ended June 30, 2015, or 4.8% of revenue, compared to $20.2 million for the six months ended June 30, 2014, or 5.0% of revenue.

Rents and leases. Rents and leases were $14.1 million for the six months ended June 30, 2015, or 1.7% of revenue, compared to $5.7 million for the six months ended June 30, 2014, or 1.4% of revenue. The $8.4 million increase was primarily attributable to rents and leases incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility rents and leases were $5.0 million for the six months ended June 30, 2015, or 1.1% of revenue, compared to $5.4 million for the six months ended June 30, 2014, or 1.3% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $91.7 million for the six months ended June 30, 2015, or 11.2% of revenue, compared to $47.8 million for the six months ended June 30, 2014, or 11.5% of revenue. The $43.9 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2014 and 2015 Acquisitions, particularly the acquisitions of Partnerships in Care and CRC. Same-facility other operating expenses were $53.7 million for the six months ended June 30, 2015, or 12.1% of revenue, compared to $46.1 million for the six months ended June 30, 2014, or 11.3% of revenue.

Depreciation and amortization. Depreciation and amortization expense was $28.0 million for the six months ended June 30, 2015, or 3.4% of revenue, compared to $11.4 million for the six months ended June 30, 2014, or 2.7% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2014 and 2015 and real estate acquired as part of the 2014 and 2015 Acquisitions, particularly the acquisition of Partnerships in Care.

Interest expense. Interest expense was $50.2 million for the six months ended June 30, 2015 compared to $19.4 million for the six months ended June 30, 2014. The increase in interest expense was primarily a result of borrowings under the Amended and Restated Senior Credit Facility, the issuance of the 5.125% Senior Notes on July 1, 2014 and the issuance of the 5.625% Senior Notes on February 11, 2015.

Loss (gain) on foreign currency derivatives. In connection with acquisitions in the United Kingdom, the Company entered into foreign currency forward contracts in March and May 2015 in order to fix the exchange rate applicable to the payment of acquisition purchase prices in April and June 2015. Unfavorable exchange rate changes resulted in a decrease in the fair value of the forward contracts and a loss on foreign currency derivatives of $0.9 million for the six months ended June 30, 2015, compared to gain of $13.7 million for the three months ended June 30, 2014 related to the acquisition of Partnerships in Care on July 1, 2014.

33

Transaction-related expenses. Transaction-related expenses were $25.6 million for the six months ended June 30, 2015 compared to $4.6 million for the six months ended June 30, 2014. Transaction-related expenses represent costs incurred in the respective periods, primarily related to the 2014 and 2015 Acquisitions, as summarized below (in thousands):

	Six Months Ended June 30,
	2015		2014
Advisory and financing commitment fees	$	10,337	$	—
Legal, accounting and other costs		9,054		4,136
Severance and contract termination costs		6,182		459
	$	25,573	$	4,595

Provision for income taxes. For the six months ended June 30, 2015, the provision for income taxes was $22.1 million, reflecting an effective tax rate of 31.4%, compared to $22.7 million, reflecting an effective tax rate of 39.0%, for the six months ended June 30, 2014. The decrease in the tax rate for the six months ended June 30, 2015 was primarily attributable to the acquisition of Partnerships in Care, which is located in a lower taxing jurisdiction and for which earnings are permanently reinvested.

Liquidity and Capital Resources

Cash provided by continuing operating activities for the six months ended June 30, 2015 was $90.6 million compared to $29.3 million for the six months ended June 30, 2014. The increase in cash provided by continuing operating activities was primarily attributable to cash provided by continuing operating activities from the 2014 and 2015 Acquisitions and the growth in same-facility operations. Days sales outstanding was 37 at both June 30, 2015 and December 31, 2014. As of June 30, 2015 and December 31, 2014, we had working capital of $82.8 million and $108.2 million, respectively.

Cash used in investing activities for the six months ended June 30, 2015 was $413.6 million compared to $72.1 million for the six months ended June 30, 2014. Cash used in investing activities for the six months ended June 30, 2015 primarily consisted of $286.7 million of cash paid for acquisitions. Cash paid for capital expenditures for the six months ended June 30, 2015 was $122.0 million, consisting of $22.7 million of routine capital expenditures and $99.3 million of expansion capital expenditures. We define expansion capital expenditures as those that increase the capacity of our facilities or otherwise enhance revenue. Routine or maintenance capital expenditures were 2.8% of revenue for the six months ended June 30, 2015. Cash paid for real estate acquisitions was $3.4 million for the six months ended June 30, 2015. Cash used in investing activities for the six months ended June 30, 2014 primarily consisted of $10.0 million of cash paid for acquisitions, $43.3 million of cash paid for capital expenditures and $18.3 million of cash paid for real estate acquisitions.

Cash provided by financing activities for the six months ended June 30, 2015 was $261.8 million compared to $316.0 million for the six months ended June 30, 2014. Cash provided by financing activities for the six months ended June 30, 2015 primarily consisted of borrowings on long-term debt of $875.0 million, borrowings on our revolving credit facility of $180.0 million, issuance of common stock of $331.5 million and an excess tax benefit from equity awards of $6.3 million, partially offset by repayment of assumed CRC debt of $904.5 million, principal payments on our revolving credit facility of $180.0 million, payment of debt issuance costs of $22.8 million, principal payments on long-term debt of $15.9 million and common stock withheld for minimum statutory taxes of $7.8 million. Cash provided by financing activities for the six months ended June 30, 2014 primarily consisted of the $374.3 million of proceeds from our issuance of common stock, borrowings on our revolving credit facility of $59.5 million, borrowings on long-term debt of $7.5 million and an excess tax benefit from equity awards of $3.5 million, partially offset by principal payments on our revolving credit facility of $113.0 million, payment of debt issuance costs of $5.8 million, principal payments on long-term debt of $3.8 million, cash paid as contingent consideration based upon earnings of Park Royal of $3.3 million and common stock withheld for minimum statutory taxes of $3.0 million.

We had total available cash and cash equivalents of $34.6 million and $94.0 million as of June 30, 2015 and December 31, 2014, respectively, of which approximately $17.4 million was held by our foreign subsidiaries for both periods. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to permanently reinvest our foreign cash and cash equivalents outside of the U.S. If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.

34

Amended and Restated Senior Credit Facility

We entered into the Senior Secured Credit Facility on April 1, 2011. On December 31, 2012, we entered into the Amended and Restated Credit Agreement which amended and restated the Senior Secured Credit Facility.

On February 13, 2014, we entered into the Fourth Amendment to the Amended and Restated Credit Agreement, to increase the size of the Amended and Restated Senior Credit Facility and extend the maturity date thereof, which resulted in the Company having a revolving line of credit of up to $300.0 million and term loans of $300.0 million. The Fourth Amendment also reduced the interest rates applicable to the Amended and Restated Senior Credit Facility and provided increased flexibility to the Company in terms of the financial and other restrictive covenants. The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.

On June 16, 2014, we entered into the Fifth Amendment to the Amended and Restated Senior Credit Facility. The Fifth Amendment specifically permitted the acquisition of Partnerships in Care, gave us the ability to incur a tranche of term loan B debt in the future through its incremental credit facility, and modified certain of the restrictive covenants on miscellaneous investments and incurrence of miscellaneous liens. The restrictive covenants on investments in joint ventures and foreign subsidiaries were also amended such that we may now invest, in any given fiscal year, up to five percent (5%) of our total assets in both joint ventures and foreign subsidiaries, respectively; provided that the aggregate amount of investments in both joint ventures and foreign subsidiaries, respectively, may not exceed ten percent (10%) of its total assets over the life of the Amended and Restated Senior Credit Facility; provided further that the aggregate amount of investments made in both joint ventures and foreign subsidiaries collectively pursuant to the foregoing may not exceed fifteen percent (15%) of our total assets. Finally, the Fifth Amendment provided increased flexibility to the Company in terms of our financial covenants.

On December 15, 2014, we entered into a Sixth Amendment to our Amended and Restated Credit Agreement. Pursuant to the Sixth Amendment, we incurred $235.0 million of additional term loans. A portion of the additional term loan advance was used to prepay our outstanding revolving loans, and a portion of the additional term loan advance was held as cash on our consolidated balance sheet. The Sixth Amendment also specifically permitted the acquisition of CRC. In connection with the acquisition of CRC, the Sixth Amendment (i) imposed a temporary reserve on our revolving credit facility in the amount of $110.0 million in order to preserve such reserved amounts for later borrowings to partially fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) (the reserve is no longer in effect due to the acquisition of CRC), (ii) permitted the incurrence of an additional incremental term loan facility under the Amended and Restated Credit Agreement partially to fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) and (iii) permitted our issuance of additional senior unsecured indebtedness or senior unsecured bridge indebtedness partially to fund the consideration for the acquisition of CRC.

On February 6, 2015, we entered into the Seventh Amendment to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.

On February 11, 2015, we entered into the First Incremental Amendment to our Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental TLB Facility that was added to the Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TLB Facility were used to fund a portion of the purchase price for our acquisition of CRC.

On April 22, 2015, we entered into an Eighth Amendment to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

We had $291.1 million of availability under the revolving line of credit as of June 30, 2015. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our outstanding term loan A loans (“TLA Facility”) of $6.7 million for June 30, 2015 to December 31, 2015, $10.0 million for March 31, 2016 to December 31, 2016, $13.4 million for March 31, 2017 to December 31, 2017, and $16.7 million for March 31, 2018 to December 31, 2018, with the remaining principal balance of the TLA Facility due on the maturity date of February 13, 2019. On December 15, 2014, prior to the execution of the Sixth Amendment, we prepaid the December 31, 2014 quarterly TLA Facility principal payment of $1.9 million. We are required to repay the TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 11, 2022.

Borrowings under the Amended and Restated Credit Agreement are guaranteed by each of our wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of our and such subsidiaries’

35

assets. Borrowings with respect to the TLA Facility and our revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 3.25% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 2.25% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at June 30, 2015. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of June 30, 2015, the Pro Rata Facilities bore interest at a rate of LIBOR plus 3.25%. In addition, we are required to pay a commitment fee on undrawn amounts under our revolving credit facility. We paid a commitment fee of 0.50% for undrawn amounts for the period from January 1, 2013 through February 12, 2014 and 0.40% for undrawn amounts for the period from February 13, 2014 through June 30, 2015. Borrowings under the Pro Rata Facilities mature on February 13, 2019.

The interest rates and the unused line fee on unused commitments related to the Pro Rata Facilities are based upon the following pricing tiers:

Pricing Tier	Consolidated Leverage Ratio	Eurodollar Rate Loans			Base Rate Loans			Commitment Fee
1	< 3.50:1.0		2.25	%		1.25	%		0.30	%
2	3.50:1.0 but < 4.00:1.0		2.50	%		1.50	%		0.35	%
3	4.00:1.0 but < 4.50:1.0		2.75	%		1.75	%		0.40	%
4	4.50:1.0 but < 5.25:1.0		3.00	%		2.00	%		0.45	%
5	5.25:1.0		3.25	%		2.25	%		0.50	%

Eurodollar Rate Loans with respect to the TLB Facility bear interest at the TLB Applicable Rate (as defined below) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans bear interest at the TLB Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “TLB Applicable Rate” means, with respect to Eurodollar Rate Loans, 3.50%, and with respect to Base Rate Loans, 2.50%.

The lenders who provided the TLB Facility are not entitled to benefit from the Company’s maintenance of its financial covenants under the Amended and Restated Credit Agreement. Accordingly, if we fail to maintain its financial covenants, such failure shall not constitute an event of default under the Amended and Restated Credit Agreement with respect to the TLB Facility until and unless the Amended and Restated Senior Credit Facility is accelerated or the commitment of the lenders to make further loans is terminated.

The Amended and Restated Credit Agreement requires us and our subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and consolidated senior secured leverage ratio. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of our material debt agreements. Set forth below is a brief description of such covenants, all of which are subject to customary exceptions, materiality thresholds and qualifications:

a) the affirmative covenants include the following: (i) delivery of financial statements and other customary financial information; (ii) notices of events of default and other material events; (iii) maintenance of existence, ability to conduct business, properties, insurance and books and records; (iv) payment of taxes; (v) lender inspection rights; (vi) compliance with laws; (vii) use of proceeds; (viii) further assurances; and (ix) additional collateral and guarantor requirements.

b) the negative covenants include limitations on the following: (i) liens; (ii) debt (including guaranties); (iii) investments; (iv) fundamental changes (including mergers, consolidations and liquidations); (v) dispositions; (vi) sale leasebacks; (vii) affiliate transactions; (viii) burdensome agreements; (ix) restricted payments; (x) use of proceeds; (xi) ownership of subsidiaries; (xii) changes to line of business; (xiii) changes to organizational documents, legal name, state of formation, form of entity and fiscal year; (xiv) prepayment or redemption of certain senior unsecured debt; and (xv) amendments to certain material agreements. The Company is generally not permitted to issue dividends or distributions other than with respect to the following: (w) certain tax distributions; (x) the repurchase of equity held by employees, officers or directors upon the occurrence of death, disability or termination subject to cap of $500,000 in any fiscal year and compliance with certain other conditions; (y) in the form of capital stock; and (z) scheduled payments of deferred purchase price, working capital adjustments and similar payments pursuant to the merger agreement or any permitted acquisition.

36

c) The financial covenants include maintenance of the following:

• the fixed charge coverage ratio may not be less than 1.25:1.00 as of the end of any fiscal quarter;

• the total leverage ratio may not be greater than the following levels as of the end of each fiscal quarter listed below:

	March 31		June 30		September 30		December 31
2014		N/A		N/A		5.75x		5.50x
2015		6.75x		6.75x		6.50x		6.00x
2016		6.00x		6.00x		6.00x		5.50x
2017		5.50x		5.50x		5.50x		5.00x
2018		5.00x		5.00x		5.00x		4.50x

• the secured leverage ratio may not be greater than the following levels as of the end of each fiscal quarter listed below:

June 30, 2014 - September 30, 2015	3.75x
December 31, 2015 and each fiscal quarter thereafter	3.50x

As of June 30, 2015, the Company was in compliance with all of the above covenants.

12.875% Senior Notes due 2018

On November 1, 2011, we issued $150.0 million of 12.875% Senior Notes due 2018 at 98.323% of the aggregate principal amount of $150.0 million, a discount of $2.5 million. The notes bear interest at a rate of 12.875% per annum. We pay interest on the notes semi-annually, in arrears, on November 1 and May 1 of each year.

The indenture governing the 12.875% Senior Notes contains covenants that, among other things, limit our ability and the ability of our restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 12.875% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

On March 12, 2013, we redeemed $52.5 million in principal amount of the 12.875% Senior Notes using a portion of the net proceeds of our December 2012 equity offering pursuant to the provision in the indenture permitting an optional redemption with equity proceeds of up to 35% of the principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were redeemed at a redemption price of 112.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date in accordance with the provisions of the indenture governing the 12.875% Senior Notes. As part of the redemption of 35% of the 12.875% Senior Notes, the Company recorded a debt extinguishment charge of $9.4 million, including the premium and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

6.125% Senior Notes Due 2021

On March 12, 2013, we issued $150.0 million of 6.125% Senior Notes due 2021. The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

The indenture governing the 6.125% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

37

The 6.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

We may redeem the 6.125% Senior Notes at our option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. We may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, we may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.125% Senior Notes due 2022

On July 1, 2014, we issued $300.0 million of 5.125% Senior Notes due 2022. The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.

The indenture governing the 5.125% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

We may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. We may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.625% Senior Notes due 2023

On February 11, 2015, we issued $375.0 million of 5.625% Senior Notes due 2023. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2015.

The indenture governing the 5.625% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.625% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

We may redeem the 5.625% Senior Notes at its option, in whole or part, at any time prior to February 15, 2018, at a price equal to 100% of the principal amount of the 5.625% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. We may redeem the 5.625% Senior Notes, in whole or in part, on or after February 15, 2018, at the redemption prices set forth in the indenture governing the 5.625% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before February 15, 2018, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.625% Senior Notes at a redemption price equal to 105.625% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

38

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of Park Royal, we assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5%, respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond-sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of June 30, 2015 and December 31, 2014, $2.3 million was recorded within other assets on the balance sheet related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the 9.0% and 9.5% Revenue Bonds using the effective interest method.

Contractual Obligations

The following table presents a summary of contractual obligations as of June 30, 2015 (dollars in thousands):

	Payments Due by Period
	Less Than 1 Year		1-3 Years		3-5 Years		More Than 5 Years		Total
Long-term debt (a)	$	133,865	$	303,140	$	515,086	$	1,540,329	$	2,492,420
Operating leases		26,258		41,046		20,975		40,909		129,188
Purchase and other obligations (b)		4,001		2,362		2,448		29,560		38,371
Total obligations and commitments	$	164,124	$	346,548	$	538,509	$	1,610,798	$	2,659,979

(a) Amounts include required principal and interest payments. The projected interest payments reflect an interest rate of 3.25% per annum for our variable-rate debt based on the rate in place as of June 30, 2015.

(b) Amounts relate to purchase obligations, including capital lease payments and contingent payments related to the acquisition of Park Royal in November 2012 that we may make depending upon achievements of certain financial targets over the four-year period ending December 31, 2016 and related to the acquisition of McCallum in September 2014 that we may make depending upon achievements of certain financial targets over the one-year period ending December 31, 2015.

Off-Balance Sheet Arrangements

As of June 30, 2015, we had standby letters of credit outstanding of $8.9 million related to security for the payment of claims as required by our workers’ compensation insurance program.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our interest expense is sensitive to changes in market interest rates. With respect to our interest-bearing liabilities, our long-term debt outstanding at June 30, 2015 was composed of $0.9 billion of fixed-rate debt and $1.0 billion of variable-rate debt with interest based on LIBOR plus an applicable margin. A hypothetical 10% increase in interest rates would decrease our net income and cash flows by $1.4 million on an annual basis based upon our borrowing level at June 30, 2015.

The functional currency for our U.K. facilities is GBP. Our revenue and earnings are sensitive to changes in GBP to USD exchange rate. As a result, our future earnings could be affected by fluctuations in the exchange rate between USD and GBP. Based upon the level of our U.K. operations relative to the Company as a whole, a hypothetical 10% change in this exchange rate would cause a change in our net income of $2.5 million for the six months ended June 30, 2015.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management conducted an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)). Based on this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that

39

information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the six months ended June 30, 2015 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

40

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are, from time to time, subject to various claims and legal actions that arise in the ordinary course of our business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, we are not currently a party to any proceeding that would have a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended June 30, 2015, the Company withheld shares of Company common stock to satisfy employee minimum statutory tax withholding obligations payable upon the vesting of restricted stock, as follows:

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
April 1 – April 30		—	$	—		—		—
May 1 – May 31		3,770		70.88		—		—
June 1 – June 30		—		—		—		—
Total		3,770

Item 6. Exhibits

Exhibit No.	Exhibit Description
3.1	Amended and Restated Certificate of Incorporation, as filed on October 28, 2011 with the Secretary of State of the State of Delaware. (1)
3.2	Amended and Restated Bylaws of Acadia Healthcare Company, Inc. (the “Company”). (1)
10.1	Eighth Amendment, dated April 22, 2015, to the Amended and Restated Credit Agreement. (2)
10.2	Underwriting Agreement, dated May 5, 2015, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC as representatives of the several underwriters named therein. (3)

41

31.1*	Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32*	Certification of Chief Executive Officer and Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document.
101.SCH**	XBRL Taxonomy Extension Schema Document.
101.CAL**	XBRL Taxonomy Calculation Linkbase Document.
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB**	XBRL Taxonomy Labels Linkbase Document.
101.PRE**	XBRL Taxonomy Presentation Linkbase Document.

(1) Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed November 1, 2011 (File No. 001-35331).

(2) Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2015 (File No. 001-35331).

(3) Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed May 6, 2015 (File No. 001-35331).

* Filed herewith.

** The XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

42

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Acadia Healthcare Company, Inc.
By:	/s/ David M. Duckworth
	David M. Duckworth
	Chief Financial Officer

Dated: August 5, 2015

43

EXHIBIT INDEX

Exhibit No.	Exhibit Description
3.1	Amended and Restated Certificate of Incorporation, as filed on October 28, 2011 with the Secretary of State of the State of Delaware. (1)
3.2	Amended and Restated Bylaws of the Company. (1)
10.1	Eighth Amendment, dated April 22, 2015, to the Amended and Restated Credit Agreement. (2)
10.2	Underwriting Agreement, dated May 5, 2015, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC as representatives of the several underwriters named therein. (3)
31.1*	Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32*	Certification of Chief Executive Officer and Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document.
101.SCH**	XBRL Taxonomy Extension Schema Document.
101.CAL**	XBRL Taxonomy Calculation Linkbase Document.
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB**	XBRL Taxonomy Labels Linkbase Document.
101.PRE**	XBRL Taxonomy Presentation Linkbase Document.

(1) Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed November 1, 2011 (File No. 001-35331).

(2) Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2015 (File No. 001-35331).

(3) Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed May 6, 2015 (File No. 001-35331).

* Filed herewith.

** The XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

44

EX-31.1

Exhibit 31.1

CERTIFICATION OF CEO PURSUANT TO

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joey A. Jacobs, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2015

/s/ Joey A. Jacobs

Joey A. Jacobs

Chairman of the Board and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF CFO PURSUANT TO

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David M. Duckworth, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2015

/s/ David M. Duckworth

David M. Duckworth

Chief Financial Officer

EX-32

Exhibit 32

CERTIFICATIONS OF CEO AND CFO PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Acadia Healthcare Company, Inc. (the “Company”) for the quarterly period ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joey A. Jacobs, Chief Executive Officer of the Company, and I, David M. Duckworth, Chief Financial Officer of the Company, each certify, for the purpose of complying with 18 U.S.C. Section 1350 and Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: August 5, 2015

/s/ Joey A. Jacobs

Joey A. Jacobs

Chairman of the Board and Chief Executive Officer

/s/ David M. Duckworth

David M. Duckworth

Chief Financial Officer

XML

Acquisitions - CRC Acquisition (Detail) $ in Millions	Feb. 11, 2015 USD ($) Beds State Center Facilities shares	Jun. 30, 2015 State
Business Acquisition [Line Items]
Number of operating states		37
CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Total consideration related to acquisition | $	$ 1,300.0
Shares issued for acquisition | shares	5,975,326
Outstanding indebtedness of CRC repaid | $	$ 904.5
Number of inpatient facilities | Facilities	35
Number of operating states	30
Number of facilities acquired | Center	81
Minimum [Member] | CRC Health Group, Inc [Member]
Business Acquisition [Line Items]
Number of beds | Beds	2,400

XML

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes due 2022 [Member] - USD ($) $ in Millions		6 Months Ended
	Jul. 01, 2014	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes	$ 300.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		Payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.
Senior notes terms		The Company may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		105.125%
Redemption percentage of senior notes		35.00%
Redemption date		Jul. 01, 2017

XML

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,540,795	$ 1,130,313
Less accumulated depreciation	(85,405)	(60,613)
Property and equipment, net	1,455,390	1,069,700
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	201,362	132,406
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,102,767	858,055
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	118,736	73,584
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 117,930	$ 66,268

XML

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Assets
Assets	$ 3,926,385	$ 2,223,590
U.S. Facilities [Member]
Assets
Assets	2,729,896	1,327,563
U.K. Facilities [Member]
Assets
Assets	944,033	726,693
Corporate and Other [Member]
Assets
Assets	$ 252,456	$ 169,334

XML

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Feb. 11, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes		$ 375.0
Debt instrument interest rate	5.625%	5.625%	5.625%
Debt instrument maturity date	Feb. 15, 2023
Date of initial payments on senior notes	Aug. 15, 2015
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage	100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage	105.625%
Redemption percentage of senior notes	35.00%
Redemption date	Feb. 15, 2018

XML

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,347	$ 3,347
Intangible assets not subject to amortization, Gross Carrying Amount	57,912	20,774
Total	61,259	24,121
Intangible assets subject to amortization, Accumulated Amortization	(2,745)	(2,485)
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(1,540)	(1,330)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,247	1,247
Intangible assets subject to amortization, Accumulated Amortization	(1,205)	(1,155)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	10,318	9,184
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	37,800	3,000
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	$ 9,794	$ 8,590

XML

Financial Information for the Company and Its Subsidiaries (Tables)

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2015

(In thousands) 

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	17,179	$	17,393	$	—		$	34,572
Accounts receivable, net		—		160,179		22,136		—			182,315
Deferred tax assets		—		36,502		2,191		—			38,693
Other current assets		—		62,295		8,030		—			70,325
Total current assets		—		276,155		49,750		—			325,905
Property and equipment, net		—		656,262		799,128		—			1,455,390
Goodwill		—		1,700,705		245,323		—			1,946,028
Intangible assets, net		—		55,928		2,586		—			58,514
Deferred tax assets – noncurrent		5,361		16,239		12,366		—			33,966
Investment in subsidiaries		1,332,308		—		—		(1,332,308	)		—
Other assets		389,676		65,957		2,322		(351,373	)		106,582
Total assets	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385
Current liabilities:
Current portion of long-term debt	$	38,437	$	—	$	215	$	—		$	38,652
Accounts payable		—		44,985		13,729		—			58,714
Accrued salaries and benefits		—		65,040		12,505		—			77,545
Other accrued liabilities		22,604		27,543		18,050		—			68,197
Total current liabilities		61,041		137,568		44,499		—			243,108
Long-term debt		—		1,890,716		375,212		(351,373	)		1,914,555
Deferred tax liabilities – noncurrent		—		—		20,200		—			20,200
Other liabilities		—		72,329		9,889		—			82,218
Total liabilities		61,041		2,100,613		449,800		(351,373	)		2,260,081
Total equity		1,666,304		670,633		661,675		(1,332,308	)		1,666,304
Total liabilities and equity	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2014

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	76,685	$	17,355	$	—		$	94,040
Accounts receivable, net		—		100,797		17,581		—			118,378
Deferred tax assets		—		18,395		1,760		—			20,155
Other current assets		—		36,049		5,521		—			41,570
Total current assets		—		231,926		42,217		—			274,143
Property and equipment, net		—		451,943		617,757		—			1,069,700
Goodwill		—		596,611		206,375		—			802,986
Intangible assets, net		—		19,057		2,579		—			21,636
Deferred tax assets – noncurrent		4,563		—		14,244		(5,666	)		13,141
Investment in subsidiaries		1,759,337		—		—		(1,759,337	)		—
Other assets		202,708		18,727		2,323		(181,774	)		41,984
Total assets	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590
Current liabilities:
Current portion of long-term debt	$	26,750	$	—	$	215	$	—		$	26,965
Accounts payable		—		39,486		9,210		—			48,696
Accrued salaries and benefits		—		47,597		11,720		—			59,317
Other accrued liabilities		13,647		7,688		9,621		—			30,956
Total current liabilities		40,397		94,771		30,766		—			165,934
Long-term debt		1,045,246		—		205,833		(181,774	)		1,069,305
Deferred tax liabilities – noncurrent		—		21,027		48,519		(5,666	)		63,880
Other liabilities		—		33,321		10,185		—			43,506
Total liabilities		1,085,643		149,119		295,303		(187,440	)		1,342,625
Total equity		880,965		1,169,145		590,192		(1,759,337	)		880,965
Total liabilities and equity	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Summary of Condensed Consolidating Statement of Comprehensive Income

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	363,851		$	97,947		$	—		$	461,798
Provision for doubtful accounts		—			(7,566	)		(572	)		—			(8,138	)
Revenue		—			356,285			97,375			—			453,660
Salaries, wages and benefits		5,355			183,490			54,457			—			243,302
Professional fees		—			22,579			7,450			—			30,029
Supplies		—			16,929			3,613			—			20,542
Rents and leases		—			7,402			809			—			8,211
Other operating expenses		—			43,145			7,983			—			51,128
Depreciation and amortization		—			10,551			4,375			—			14,926
Interest expense, net		18,106			5,882			4,061			—			28,049
Loss on foreign currency derivatives		961			—			—			—			961
Transaction-related expenses		—			2,946			4,211			—			7,157
Total expenses		24,422			292,924			86,959			—			404,305
(Loss) income from continuing operations before income taxes		(24,422	)		63,361			10,416			—			49,355
Equity in earnings of subsidiaries		50,281			—			—			(50,281	)		—
(Benefit from) provision for income taxes		(7,985	)		20,734			2,763			—			15,512
Income (loss) from continuing operations		33,844			42,627			7,653			(50,281	)		33,843
Income from discontinued operations, net of income taxes		—			1			—			—			1
Net income (loss)	$	33,844		$	42,628		$	7,653		$	(50,281	)	$	33,844
Other comprehensive income:
Foreign currency translation gain		—			—			46,173			—			46,173
Other comprehensive income		—			—			46,173			—			46,173
Comprehensive income (loss)	$	33,844		$	42,628		$	53,826		$	(50,281	)	$	80,017

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	207,143		$	13,521		$	—		$	220,664
Provision for doubtful accounts		—			(5,954	)		(907	)		—			(6,861	)
Revenue		—			201,189			12,614			—			213,803
Salaries, wages and benefits		2,406			114,976			5,091			—			122,473
Professional fees		—			9,691			1,200			—			10,891
Supplies		—			9,967			629			—			10,596
Rents and leases		—			2,613			276			—			2,889
Other operating expenses		—			22,522			2,124			—			24,646
Depreciation and amortization		—			5,581			354			—			5,935
Interest expense, net		9,202			—			528			—			9,730
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			3,016			—			—			3,016
Total expenses		(2,127	)		168,366			10,202			—			176,441
Income from continuing operations before income taxes		2,127			32,823			2,412			—			37,362
Equity in earnings of subsidiaries		20,972			—			—			(20,972	)		—
Provision for income taxes		648			13,315			942			—			14,905
Income (loss) from continuing operations		22,451			19,508			1,470			(20,972	)		22,457
Loss from discontinued operations, net of income taxes		—			(6	)		—			—			(6	)
Net income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451
Comprehensive income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	651,616		$	184,340		$	—		$	835,956
Provision for doubtful accounts		—			(14,985	)		(1,528	)		—			(16,513	)
Revenue		—			636,631			182,812			—			819,443
Salaries, wages and benefits		9,249			339,189			100,735			—			449,173
Professional fees		—			39,064			13,392			—			52,456
Supplies		—			29,938			6,858			—			36,796
Rents and leases		—			12,519			1,578			—			14,097
Other operating expenses		—			75,392			16,263			—			91,655
Depreciation and amortization		—			19,262			8,768			—			28,030
Interest expense, net		31,054			11,603			7,538			—			50,195
Loss on foreign currency derivatives		908			—			—			—			908
Transaction-related expenses		—			21,362			4,211			—			25,573
Total expenses		41,211			548,329			159,343			—			748,883
(Loss) income from continuing operations before income taxes		(41,211	)		88,302			23,469			—			70,560
Equity in earnings of subsidiaries		76,268			—			—			(76,268	)		—
(Benefit from) provision for income taxes		(13,381	)		29,251			6,255			—			22,125
Income (loss) from continuing operations		48,438			59,051			17,214			(76,268	)		48,435
Income from discontinued operations, net of income taxes		—			3			—			—			3
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Other comprehensive income:
Foreign currency translation gain		—			—			16,784			—			16,784
Other comprehensive income		—			—			16,784			—			16,784
Comprehensive income (loss)	$	48,438		$	59,054		$	33,998		$	(76,268	)	$	65,222

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	400,425		$	26,358		$	—		$	426,783
Provision for doubtful accounts		—			(10,464	)		(1,098	)		—			(11,562	)
Revenue		—			389,961			25,260			—			415,221
Salaries, wages and benefits		4,170			225,629			10,249			—			240,048
Professional fees		—			18,944			2,329			—			21,273
Supplies		—			19,353			1,307			—			20,660
Rents and leases		—			5,108			550			—			5,658
Other operating expenses		—			43,600			4,156			—			47,756
Depreciation and amortization		—			10,666			705			—			11,371
Interest expense, net		18,313			—			1,124			—			19,437
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			4,595			—			—			4,595
Total expenses		8,748			327,895			20,420			—			357,063
(Loss) income from continuing operations before income taxes		(8,748	)		62,066			4,840			—			58,158
Equity in earnings of subsidiaries		40,839			—			—			(40,839	)		—
(Benefit from) provision for income taxes		(3,418	)		24,249			1,849			—			22,680
Income (loss) from continuing operations		35,509			37,817			2,991			(40,839	)		35,478
Income from discontinued operations, net of income taxes		—			31			—			—			31
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Comprehensive income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(76,268	)		—			—			76,268			—
Depreciation and amortization		—			19,262			8,768			—			28,030
Amortization of debt issuance costs		—			3,438			(220	)		—			3,218
Equity-based compensation expense		9,249			—			—			—			9,249
Deferred income tax (benefit) expense		(798	)		22,964			2,516			—			24,682
Loss from discontinued operations, net of taxes		—			(3	)		—			—			(3	)
Loss (gain) on foreign currency derivatives		908			—			—			—			908
Other		—			662			30			—			692
Change in operating assets and liabilities, net of effect of acquisitions:											—
Accounts receivable, net		—			(11,409	)		967			—			(10,442	)
Other current assets		—			(12,026	)		(1,022	)		—			(13,048	)
Other assets		(300	)		(1,220	)		2			300			(1,218	)
Accounts payable and other accrued liabilities		—			5,991			(10,304	)		—			(4,313	)
Accrued salaries and benefits		—			791			(1,016	)		—			(225	)
Other liabilities		—			5,442			(823	)		—			4,619
Net cash (used in) provided by continuing operating activities		(18,771	)		92,946			16,112			300			90,587
Net cash provided by discontinued operating activities		—			554			—			—			554
Net cash (used in) provided by operating activities		(18,771	)		93,500			16,112			300			91,141
Investing activities:											—
Cash paid for acquisitions, net of cash acquired		—			(89,041	)		(197,693	)		—			(286,734	)
Cash paid for capital expenditures		—			(62,101	)		(59,934	)		—			(122,035	)
Cash paid for real estate acquisitions		—			(3,428	)		—			—			(3,428	)
Settlement of foreign currency derivatives		—			(908	)		—			—			(908	)
Other		—			(481	)		—			—			(481	)
Net cash used in investing activities		—			(155,959	)		(257,627	)		—			(413,586	)
Financing activities:											—
Borrowings on long-term debt		875,000			—			—			—			875,000
Borrowings on revolving credit facility		180,000			—			—			—			180,000
Principal payments on revolving credit facility		(180,000	)		—			—			—			(180,000	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Principal payments on long-term debt		(15,875	)		—			(300	)		300			(15,875	)
Payment of debt issuance costs		—			(22,775	)		—			—			(22,775	)
Issuance of Common Stock		—			331,530			—			—			331,530
Common stock withheld for minimum statutory taxes, net		—			(7,826	)		—			—			(7,826	)
Excess tax benefit from equity awards		—			6,327			—			—			6,327
Other		—			(150	)		—			—			(150	)
Cash provided by (used in) intercompany activity		64,113			(305,366	)		241,853			(600	)		—
Net cash provided by (used in) financing activities		18,771			1,740			241,553			(300	)		261,764
Effect of exchange rate changes on cash		—			1,213			—			—			1,213
Net (decrease) increase in cash and cash equivalents		—			(59,506	)		38			—			(59,468	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040
Cash and cash equivalents at end of the period	$	—		$	17,179		$	17,393		$	—		$	34,572

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(40,839	)		—			—			40,839			—
Depreciation and amortization		—			10,666			705			—			11,371
Amortization of debt issuance costs		1,560			—			(226	)		—			1,334
Equity-based compensation expense		4,170			—			—			—			4,170
Deferred income tax expense		5,585			3,105			407			—			9,097
Income from discontinued operations, net of taxes		—			(31	)		—			—			(31	)
Gain on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Other		—			25			—			—			25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(16,670	)		1,367			—			(15,303	)
Other current assets		—			(5,033	)		241			—			(4,792	)
Other assets		165			(578	)		—			(165	)		(578	)
Accounts payable and other accrued liabilities		—			(1,584	)		284			—			(1,300	)
Accrued salaries and benefits		—			1,701			81			—			1,782
Other liabilities		—			1,701			—			—			1,701
Net cash (used in) provided by continuing operating activities		(7,585	)		31,150			5,850			(165	)		29,250
Net cash used in discontinued operating activities		—			(11	)		—			—			(11	)
Net cash (used in) provided by operating activities		(7,585	)		31,139			5,850			(165	)		29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(10,000	)		—			—			(10,000	)
Cash paid for capital expenditures		—			(39,782	)		(3,541	)		—			(43,323	)
Cash paid for real estate acquisitions		—			(18,326	)		—			—			(18,326	)
Other		—			(439	)		—			—			(439	)
Net cash used in investing activities		—			(68,547	)		(3,541	)		—			(72,088	)
Financing activities:
Borrowings on long-term debt		7,500			—			—			—			7,500
Borrowings on revolving credit facility		59,500			—			—			—			59,500
Principal payments on revolving credit facility		(113,000	)		—			—			—			(113,000	)
Principal payments on long-term debt		(3,750	)		—			(165	)		165			(3,750	)
Payment of debt issuance costs		(5,810	)		—			—			—			(5,810	)
Issuance of common stock, net		374,336			—			—			—			374,336
Common stock withheld for minimum statutory taxes, net		(2,981	)		—			—			—			(2,981	)
Excess tax benefit from equity awards		3,479			—			—			—			3,479
Cash paid for contingent consideration		—			(3,250	)		—			—			(3,250	)
Cash (used in) provided by intercompany activity		(311,689	)		315,175			(5,411	)		1,925			—
Net cash provided by (used in) financing activities		7,585			311,925			(5,576	)		2,090			316,024
Net increase (decrease) in cash and cash equivalents		—			274,517			(3,267	)		1,925			273,175
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569
Cash and cash equivalents at end of the period	$	—		$	274,517		$	3,227		$	—		$	277,744

XML

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Jun. 30, 2015
12.875% Senior Notes Due 2018 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	12.875%
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%
5.125% Senior Notes due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%

XML

Equity Offerings - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands				6 Months Ended
	May. 11, 2015	Feb. 11, 2015	Jun. 17, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Equity [Line Items]
Common stock offered	5,175,000		8,881,794	70,596,523		59,211,859
Common stock offer price	$ 66.50		$ 44.00	$ 0.01		$ 0.01
Underwriting discount amount	$ 12,000		$ 15,600
Additional offering-related costs	600		800
Net proceeds from sale of shares	$ 331,500		$ 374,400	$ 331,530	$ 374,336
CRC Health Group, Inc [Member]
Equity [Line Items]
Total consideration related to acquisition		$ 1,300,000
Shares issued for acquisition		5,975,326

XML

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Operating activities:
Net income (loss)	$ 33,844	$ 22,451	$ 48,438	$ 35,509
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	14,926	5,935	28,030	11,371
Amortization of debt issuance costs			3,218	1,334
Equity-based compensation expense	5,355	2,406	9,249	4,170
Deferred income tax (benefit) expense			24,682	9,097
Income (loss) from discontinued operations, net of income taxes	(1)	6	(3)	(31)
Loss (gain) on foreign currency derivatives	961	(13,735)	908	(13,735)
Other			692	25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(10,442)	(15,303)
Other current assets			(13,048)	(4,792)
Other assets			(1,218)	(578)
Accounts payable and other accrued liabilities			(4,313)	(1,300)
Accrued salaries and benefits			(225)	1,782
Other liabilities			4,619	1,701
Net cash provided by continuing operating activities			90,587	29,250
Net cash provided by discontinued operating activities			554	(11)
Net cash (used in) provided by operating activities			91,141	29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired			(286,734)	(10,000)
Cash paid for capital expenditures			(122,035)	(43,323)
Cash paid for real estate acquisitions			(3,428)	(18,326)
Settlement of foreign currency derivatives			(908)
Other			(481)	(439)
Net cash used in investing activities			(413,586)	(72,088)
Financing activities:
Borrowings on long-term debt			875,000	7,500
Borrowings on revolving credit facility			180,000	59,500
Principal payments on revolving credit facility			(180,000)	(113,000)
Repayment of assumed CRC debt			(904,467)
Principal payments on long-term debt			(15,875)	(3,750)
Payment of debt issuance costs			(22,775)	(5,810)
Issuance of common stock, net			(380,210)	374,336
Common stock withheld for minimum statutory taxes, net			(7,826)	(2,981)
Excess tax benefit from equity awards			6,327	3,479
Other			(150)
Cash paid for contingent consideration				(3,250)
Net cash provided by (used in) financing activities			261,764	316,024
Effect of exchange rate changes on cash			1,213
Net (decrease) increase in cash and cash equivalents			(59,468)	273,175
Cash and cash equivalents at beginning of the period			94,040	4,569	$ 4,569
Cash and cash equivalents at end of the period	34,572	277,744	34,572	277,744	94,040
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)	(50,281)	(20,972)	(76,268)	(40,839)
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	50,281	20,972	76,268	40,839
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets			300	(165)
Net cash provided by continuing operating activities			300	(165)
Net cash (used in) provided by operating activities			300	(165)
Financing activities:
Principal payments on long-term debt			300	165
Cash provided by (used in) intercompany activity			(600)	1,925
Net cash provided by (used in) financing activities			(300)	2,090
Net (decrease) increase in cash and cash equivalents				1,925
Cash and cash equivalents at beginning of the period				(1,925)	(1,925)
Parent [Member]
Operating activities:
Net income (loss)	33,844	22,451	48,438	35,509
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries	(50,281)	(20,972)	(76,268)	(40,839)
Amortization of debt issuance costs				1,560
Equity-based compensation expense			9,249	4,170
Deferred income tax (benefit) expense			(798)	5,585
Loss (gain) on foreign currency derivatives	961	(13,735)	908	(13,735)
Change in operating assets and liabilities, net of effect of acquisitions:
Other assets			(300)	165
Net cash provided by continuing operating activities			(18,771)	(7,585)
Net cash (used in) provided by operating activities			(18,771)	(7,585)
Financing activities:
Borrowings on long-term debt			875,000	7,500
Borrowings on revolving credit facility			180,000	59,500
Principal payments on revolving credit facility			(180,000)	(113,000)
Repayment of assumed CRC debt			(904,467)
Principal payments on long-term debt			(15,875)	(3,750)
Payment of debt issuance costs				(5,810)
Issuance of common stock, net				374,336
Common stock withheld for minimum statutory taxes, net				(2,981)
Excess tax benefit from equity awards				3,479
Cash provided by (used in) intercompany activity			64,113	(311,689)
Net cash provided by (used in) financing activities			18,771	7,585
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)	42,628	19,502	59,054	37,848
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	10,551	5,581	19,262	10,666
Amortization of debt issuance costs			3,438
Deferred income tax (benefit) expense			22,964	3,105
Income (loss) from discontinued operations, net of income taxes	(1)	6	(3)	(31)
Other			662	25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(11,409)	(16,670)
Other current assets			(12,026)	(5,033)
Other assets			(1,220)	(578)
Accounts payable and other accrued liabilities			5,991	(1,584)
Accrued salaries and benefits			791	1,701
Other liabilities			5,442	1,701
Net cash provided by continuing operating activities			92,946	31,150
Net cash provided by discontinued operating activities			554	(11)
Net cash (used in) provided by operating activities			93,500	31,139
Investing activities:
Cash paid for acquisitions, net of cash acquired			(89,041)	(10,000)
Cash paid for capital expenditures			(62,101)	(39,782)
Cash paid for real estate acquisitions			(3,428)	(18,326)
Settlement of foreign currency derivatives			(908)
Other			(481)	(439)
Net cash used in investing activities			(155,959)	(68,547)
Financing activities:
Payment of debt issuance costs			(22,775)
Issuance of common stock, net			331,530
Common stock withheld for minimum statutory taxes, net			(7,826)
Excess tax benefit from equity awards			6,327
Other			(150)
Cash paid for contingent consideration				(3,250)
Cash provided by (used in) intercompany activity			(305,366)	315,175
Net cash provided by (used in) financing activities			1,740	311,925
Effect of exchange rate changes on cash			1,213
Net (decrease) increase in cash and cash equivalents			(59,506)	274,517
Cash and cash equivalents at beginning of the period			76,685
Cash and cash equivalents at end of the period	17,179	274,517	17,179	274,517	76,685
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)	7,653	1,470	17,214	2,991
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Depreciation and amortization	4,375	354	8,768	705
Amortization of debt issuance costs			(220)	(226)
Deferred income tax (benefit) expense			2,516	407
Other			30
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			967	1,367
Other current assets			(1,022)	241
Other assets			2
Accounts payable and other accrued liabilities			(10,304)	284
Accrued salaries and benefits			(1,016)	81
Other liabilities			(823)
Net cash provided by continuing operating activities			16,112	5,850
Net cash (used in) provided by operating activities			16,112	5,850
Investing activities:
Cash paid for acquisitions, net of cash acquired			(197,693)
Cash paid for capital expenditures			(59,934)	(3,541)
Net cash used in investing activities			(257,627)	(3,541)
Financing activities:
Principal payments on long-term debt			(300)	(165)
Cash provided by (used in) intercompany activity			241,853	(5,411)
Net cash provided by (used in) financing activities			241,553	(5,576)
Net (decrease) increase in cash and cash equivalents			38	(3,267)
Cash and cash equivalents at beginning of the period			17,355	6,494	6,494
Cash and cash equivalents at end of the period	$ 17,393	$ 3,227	$ 17,393	$ 3,227	$ 17,355

XML

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 1,455,390	$ 1,069,700
U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	671,200	478,100
U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	754,200	578,600
Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 30,000	$ 13,000

XML

Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2015 and 2014 (in thousands except per share amounts):

	Three Months Ended June 30,					Six Months Ended June 30,
	2015		2014			2015		2014
Numerator:
Basic and diluted earnings per share:
Income from continuing operations	$	33,843	$	22,457		$	48,435	$	35,478
Income (loss) from discontinued operations		1		(6	)		3		31
Net income	$	33,844	$	22,451		$	48,438	$	35,509
Denominator:
Weighted average shares outstanding for basic earnings per share		68,296		51,616			65,429		50,872
Effect of dilutive instruments		439		203			353		302
Shares used in computing diluted earnings per common share		68,735		51,819			65,782		51,174
Basic earnings per share:
Income from continuing operations	$	0.50	$	0.43		$	0.74	$	0.70
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.50	$	0.43		$	0.74	$	0.70
Diluted earnings per share:
Income from continuing operations	$	0.49	$	0.43		$	0.74	$	0.69
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.49	$	0.43		$	0.74	$	0.69

XML

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013	Nov. 01, 2011
12.875% Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	12.875%	12.875%			12.875%	12.875%
Senior notes maturity year	2018	2018
Debt instrument discount	$ 967	$ 1,080				$ 2,500
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%			6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%		5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%	5.625%
Senior notes maturity year	2023	2023
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument premium	$ 1,429	$ 1,649
9.0% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.00%	9.00%
9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	9.50%	9.50%
Senior Secured Term A Loans [Member] | Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument discount	$ 1,628	$ 1,924
Senior Secured Term B Loans [Member] | Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument discount	$ 2,377

XML

Acquisitions - Summary of Acquisitions (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 1,946,028	$ 802,986
2014 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		11,674
Accounts receivable		9,533
Prepaid expenses and other current assets		8,997
Property and equipment		637,680
Goodwill		119,279
Intangible assets		855
Other assets		10,277
Total assets acquired		798,295
Accounts payable		4,051
Accrued salaries and benefits		10,422
Other accrued expenses		8,180
Deferred tax liabilities - noncurrent		15,597
Other liabilities		7,704
Total liabilities assumed		45,954
Net assets acquired		752,341
2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	24,068
Accounts receivable	53,225
Prepaid expenses and other current assets	26,902
Property and equipment	278,765
Goodwill	1,169,106
Intangible assets	37,000
Deferred tax assets - noncurrent	64,688
Other assets	6,478
Total assets acquired	1,660,232
Accounts payable	12,415
Accrued salaries and benefits	16,502
Other accrued expenses	41,249
Deferred tax liabilities - noncurrent	1,052
Long-term debt	904,467
Other liabilities	34,259
Total liabilities assumed	1,009,944
Net assets acquired	650,288
Partnerships In Care [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Cash		11,674
Accounts receivable		7,684
Prepaid expenses and other current assets		8,828
Property and equipment		610,477
Goodwill		87,047
Intangible assets		651
Other assets		7,037
Total assets acquired		733,398
Accounts payable		3,958
Accrued salaries and benefits		10,422
Other accrued expenses		7,166
Deferred tax liabilities - noncurrent		15,597
Other liabilities		7,704
Total liabilities assumed		44,847
Net assets acquired		688,551
Other [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable		1,849
Prepaid expenses and other current assets		169
Property and equipment		27,203
Goodwill		32,232
Intangible assets		204
Other assets		3,240
Total assets acquired		64,897
Accounts payable		93
Other accrued expenses		1,014
Total liabilities assumed		1,107
Net assets acquired		$ 63,790
Other [Member] | 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	4,468
Accounts receivable	6,130
Prepaid expenses and other current assets	1,380
Property and equipment	138,613
Goodwill	118,486
Total assets acquired	269,077
Accounts payable	7,114
Accrued salaries and benefits	1,642
Other accrued expenses	2,546
Deferred tax liabilities - noncurrent	1,052
Other liabilities	11
Total liabilities assumed	12,365
Net assets acquired	256,712
CRC Health Group, Inc [Member] | 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Cash	19,600
Accounts receivable	47,095
Prepaid expenses and other current assets	25,522
Property and equipment	140,152
Goodwill	1,050,620
Intangible assets	37,000
Deferred tax assets - noncurrent	64,688
Other assets	6,478
Total assets acquired	1,391,155
Accounts payable	5,301
Accrued salaries and benefits	14,860
Other accrued expenses	38,703
Long-term debt	904,467
Other liabilities	34,248
Total liabilities assumed	997,579
Net assets acquired	$ 393,576

XML

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	$ 461,798	$ 220,664	$ 835,956	$ 426,783
Provision for doubtful accounts	(8,138)	(6,861)	(16,513)	(11,562)
Revenue	453,660	213,803	819,443	415,221
Salaries, wages and benefits	243,302	122,473	449,173	240,048
Professional fees	30,029	10,891	52,456	21,273
Supplies	20,542	10,596	36,796	20,660
Rents and leases	8,211	2,889	14,097	5,658
Other operating expenses	51,128	24,646	91,655	47,756
Depreciation and amortization	14,926	5,935	28,030	11,371
Interest expense, net	28,049	9,730	50,195	19,437
Loss (gain) on foreign currency derivatives	961	(13,735)	908	(13,735)
Transaction-related expenses	7,157	3,016	25,573	4,595
Total expenses	404,305	176,441	748,883	357,063
(Loss) income from continuing operations before income taxes	49,355	37,362	70,560	58,158
(Benefit from) provision for income taxes	15,512	14,905	22,125	22,680
Income (loss) from continuing operations	33,843	22,457	48,435	35,478
Income (loss) from discontinued operations, net of income taxes	1	(6)	3	31
Net income (loss)	33,844	22,451	48,438	35,509
Other comprehensive income:
Foreign currency translation gain	46,173		16,784
Other comprehensive income	46,173		16,784
Comprehensive income (loss)	80,017	22,451	65,222	35,509
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(50,281)	(20,972)	(76,268)	(40,839)
Income (loss) from continuing operations	(50,281)	(20,972)	(76,268)	(40,839)
Net income (loss)	(50,281)	(20,972)	(76,268)	(40,839)
Other comprehensive income:
Comprehensive income (loss)	(50,281)	(20,972)	(76,268)	(40,839)
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	5,355	2,406	9,249	4,170
Interest expense, net	18,106	9,202	31,054	18,313
Loss (gain) on foreign currency derivatives	961	(13,735)	908	(13,735)
Total expenses	24,422	(2,127)	41,211	8,748
(Loss) income from continuing operations before income taxes	(24,422)	2,127	(41,211)	(8,748)
Equity in earnings of subsidiaries	50,281	20,972	76,268	40,839
(Benefit from) provision for income taxes	(7,985)	648	(13,381)	(3,418)
Income (loss) from continuing operations	33,844	22,451	48,438	35,509
Net income (loss)	33,844	22,451	48,438	35,509
Other comprehensive income:
Comprehensive income (loss)	33,844	22,451	48,438	35,509
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	363,851	207,143	651,616	400,425
Provision for doubtful accounts	(7,566)	(5,954)	(14,985)	(10,464)
Revenue	356,285	201,189	636,631	389,961
Salaries, wages and benefits	183,490	114,976	339,189	225,629
Professional fees	22,579	9,691	39,064	18,944
Supplies	16,929	9,967	29,938	19,353
Rents and leases	7,402	2,613	12,519	5,108
Other operating expenses	43,145	22,522	75,392	43,600
Depreciation and amortization	10,551	5,581	19,262	10,666
Interest expense, net	5,882		11,603
Transaction-related expenses	2,946	3,016	21,362	4,595
Total expenses	292,924	168,366	548,329	327,895
(Loss) income from continuing operations before income taxes	63,361	32,823	88,302	62,066
(Benefit from) provision for income taxes	20,734	13,315	29,251	24,249
Income (loss) from continuing operations	42,627	19,508	59,051	37,817
Income (loss) from discontinued operations, net of income taxes	1	(6)	3	31
Net income (loss)	42,628	19,502	59,054	37,848
Other comprehensive income:
Comprehensive income (loss)	42,628	19,502	59,054	37,848
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue before provision for doubtful accounts	97,947	13,521	184,340	26,358
Provision for doubtful accounts	(572)	(907)	(1,528)	(1,098)
Revenue	97,375	12,614	182,812	25,260
Salaries, wages and benefits	54,457	5,091	100,735	10,249
Professional fees	7,450	1,200	13,392	2,329
Supplies	3,613	629	6,858	1,307
Rents and leases	809	276	1,578	550
Other operating expenses	7,983	2,124	16,263	4,156
Depreciation and amortization	4,375	354	8,768	705
Interest expense, net	4,061	528	7,538	1,124
Transaction-related expenses	4,211		4,211
Total expenses	86,959	10,202	159,343	20,420
(Loss) income from continuing operations before income taxes	10,416	2,412	23,469	4,840
(Benefit from) provision for income taxes	2,763	942	6,255	1,849
Income (loss) from continuing operations	7,653	1,470	17,214	2,991
Net income (loss)	7,653	1,470	17,214	2,991
Other comprehensive income:
Foreign currency translation gain	46,173		16,784
Other comprehensive income	46,173		16,784
Comprehensive income (loss)	$ 53,826	$ 1,470	$ 33,998	$ 2,991

XML

Acquisitions - UK Acquisitions (Detail) - United Kingdom [Member] $ in Millions	Jun. 01, 2015 USD ($) Beds Facility	Apr. 01, 2015 USD ($) Beds Facility
Care UK Limited [Member]
Business Acquisition [Line Items]
Business acquisition cash paid	$ 88.3
Number of facilities acquired | Facility	15
Number of beds | Beds	299
Choice Lifestyles [Member]
Business Acquisition [Line Items]
Business acquisition cash paid	$ 25.9	$ 37.5
Number of facilities acquired | Facility	1	2
Number of beds | Beds	42	48
Pastoral Care Group [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 34.2
Number of facilities acquired | Facility		2
Number of beds | Beds		65
Mildmay Oaks [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 14.9
Number of beds | Beds		67

XML

Long-Term Debt (12.875% Senior Notes due 2018) - Additional Information (Detail) - 12.875% Senior Notes Due 2018 [Member] - USD ($) $ in Thousands		6 Months Ended
	Mar. 12, 2013	Jun. 30, 2015	Dec. 31, 2014	Nov. 01, 2011
Debt Instrument [Line Items]
Issued Senior Notes				$ 150,000
Issue rate of senior notes				98.323%
Debt instrument discount		$ 967	$ 1,080	$ 2,500
Senior notes interest percentage	12.875%	12.875%	12.875%	12.875%
Interest on the notes		Semi-annually, in arrears, on November 1 and May 1 of each year
Debt instrument, maximum redemption amount	$ 52,500
Debt instrument, redemption price percentage	112.875%
Redemption percentage of senior notes	35.00%
Debt extinguishment charge	$ 9,400

XML

Segment Information - Additional Information (Detail) - Jun. 30, 2015	Beds State Facilities
Segment Reporting Information [Line Items]
Number of facilities	223
Number of beds | Beds	9,000
Number of operating states | State	37
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities	178
Number of operating states | State	37
U.S. Facilities [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Number of beds | Beds	7,200
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities	45
U.K. Facilities [Member] | Minimum [Member]
Segment Reporting Information [Line Items]
Number of beds | Beds	1,800

XML

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	125,113	95,751
Granted, Number of Units	217,994	108,449
Cancelled, Number of Units	0	0
Vested, Number of Units	(125,023)	(79,087)
Unvested, Number of Shares/Units, Ending balance	218,084	125,113
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 38.73	$ 23.05
Granted, Weighted Average Grant-Date Fair Value	61.77	50.75
Cancelled, Weighted Average Grant-Date Fair Value	0	0
Vested, Weighted Average Grant-Date Fair Value	32.38	21.81
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 56.97	$ 38.73

XML

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Amortization expense	$ 0.1	$ 0.1	$ 0.3	$ 0.3
Estimated amortization expense, remainder of 2015	0.5		0.5
Estimated amortization expense, 2016	0.4		0.4
Estimated amortization expense, 2017	0.0		0.0
Estimated amortization expense, 2018	0.0		0.0
Estimated amortization expense, 2019	$ 0.0		0.0
Licenses and Accreditations [Member] | CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			1.1
Trade Names [Member] | CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			34.8
Certificates of Need [Member] | CRC Health Group, Inc [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Acquisition of intangible assets with a preliminary fair value			$ 1.1

XML

Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico. At June 30, 2015, the Company operated 223 behavioral healthcare facilities with over 9,000 beds in 37 states, the United Kingdom and Puerto Rico.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations, each of which is a direct or indirect wholly-owned subsidiary of the Company. The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, all of which are 100% owned. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Certain reclassifications have been made to prior years to conform to the current year presentation.

XML

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value of options	$ 24.30	$ 17.14
Risk-free interest rate	1.90%	1.70%
Expected volatility	33.00%	36.00%
Expected life (in years)	5 years 6 months	5 years 6 months

XML

Acquisitions - Other (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Combinations [Abstract]
Advisory and financing commitment fees			$ 10,337
Legal, accounting and other costs	$ 5,234	$ 3,016	9,054	$ 4,136
Severance and contract termination costs	1,923		6,182	459
Transaction-related expenses	$ 7,157	$ 3,016	$ 25,573	$ 4,595

XML

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2015			December 31, 2014
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans (net of discount of $1,628 and $1,924, respectively)	$	512,497		$	525,576
Senior Secured Term B Loans (net of discount of $2,377)		495,123			—
Senior Secured Revolving Line of Credit		—			—
12.875% Senior Notes due 2018 (net of discount of $967 and $1,080, respectively)		96,533			96,420
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		375,000			—
9.0% and 9.5% Revenue Bonds (net of premium of $1,429 and $1,649, respectively)		24,054			24,274
		1,953,207			1,096,270
Less: current portion		(38,652	)		(26,965	)
Long-term debt	$	1,914,555		$	1,069,305

XML

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	June 30, 2015			December 31, 2014
Land	$	201,362		$	132,406
Building and improvements		1,102,767			858,055
Equipment		118,736			73,584
Construction in progress		117,930			66,268
		1,540,795			1,130,313
Less accumulated depreciation		(85,405	)		(60,613	)
Property and equipment, net	$	1,455,390		$	1,069,700

XML

Long-Term Debt (9.0% and 9.5% Revenue Bonds) - Additional Information (Detail) - 9.0% and 9.5% Revenue Bonds [Member] - USD ($) $ in Thousands	Nov. 11, 2012	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds		$ 24,054	$ 24,274
Debt instrument premium		1,429	1,649
Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 23,000
Debt service reserve fund within other assets		$ 2,300	$ 2,300
Debt instrument premium	2,600
Fair Value Measurement [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	25,600
9.0% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 7,500
Debt instrument interest rate	9.00%
Debt instrument maturity date	Dec. 01, 2030
9.5% Revenue Bonds [Member] | Park Royal [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 15,500
Debt instrument interest rate	9.50%
Debt instrument maturity date	Dec. 01, 2040

XML

Acquisitions - Pro Forma Information 1 (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Acquisition [Line Items]
Revenue	$ 453,660	$ 213,803	$ 819,443	$ 415,221
Income (loss) from continuing operations	49,355	37,362	70,560	58,158
Acquisitions Completed in 2014 And 2015 [Member]
Business Acquisition [Line Items]
Revenue	222,100		369,700
Income (loss) from continuing operations	$ 37,600		$ 58,100
Acquisitions Completed in 2014 [Member]
Business Acquisition [Line Items]
Revenue		1,600		2,900
Income (loss) from continuing operations		$ 100		$ (100)

XML

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Activity

Stock option activity during 2014 and 2015 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2014		798,809		$	21.93		8.20	$	10,700
Options granted		226,663			49.80		9.25		209
Options exercised		(210,199	)		14.93		N/A		4,994
Options cancelled		(77,851	)		27.85		N/A		N/A
Options outstanding at December 31, 2014		737,422			32.19		8.09		14,512
Options granted		190,900			62.37		9.68		1,148
Options exercised		(49,045	)		23.66		N/A		5,197
Options cancelled		(88,264	)		47.86		N/A		N/A
Options outstanding at June 30, 2015		791,013		$	40.28		8.09	$	23,104
Options exercisable at December 31, 2014		91,947		$	28.87		6.30	$	3,326
Options exercisable at June 30, 2015		153,900		$	34.84		6.60	$	6,941

Restricted Stock Activity

Restricted stock activity during 2014 and 2015 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		461,697		$	24.96
Granted		468,484			48.99
Cancelled		(75,369	)		36.36
Vested		(132,784	)		22.81
Unvested at December 31, 2014		722,028		$	39.77
Granted		480,152			62.08
Cancelled		(55,674	)		49.59
Vested		(107,263	)		32.47
Unvested at June 30, 2015		1,039,243		$	51.03

Restricted Stock Unit Activity

Restricted stock unit activity during 2014 and 2015 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		95,751		$	23.05
Granted		108,449			50.75
Cancelled		—			—
Vested		(79,087	)		21.81
Unvested at December 31, 2014		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38
Unvested at June 30, 2015		218,084		$	56.97

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2015 and year ended December 31, 2014:

	June 30, 2015			December 31, 2014
Weighted average grant-date fair value of options	$	24.30		$	17.14
Risk-free interest rate		1.9	%		1.7	%
Expected volatility		33	%		36	%
Expected life (in years)		5.5			5.5

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liability

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of June 30, 2015 and December 31, 2014 were as follows (in thousands):

	Carrying Amount				Fair Value
	June 30, 2015		December 31, 2014		June 30, 2015		December 31, 2014
Amended and Restated Senior Credit Facility	$	1,007,620	$	525,576	$	1,007,620	$	525,576
12.875% Senior Notes due 2018	$	96,533	$	96,420	$	106,519	$	109,688
6.125% Senior Notes due 2021	$	150,000	$	150,000	$	154,500	$	153,000
5.125% Senior Notes due 2022	$	300,000	$	300,000	$	297,750	$	295,500
5.625% Senior Notes due 2023	$	375,000		—	$	379,688		—
9.0% and 9.5% Revenue Bonds	$	24,054	$	24,274	$	24,054	$	24,274
Contingent consideration liabilities	$	3,000	$	3,000	$	3,000	$	3,000

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net income	$ 48,438	$ 35,509
Adjustments to reconcile net income to net cash provided by continuing operating activities:
Depreciation and amortization	28,030	11,371
Amortization of debt issuance costs	3,218	1,334
Equity-based compensation expense	9,249	4,170
Deferred income tax expense	24,682	9,097
Income from discontinued operations, net of taxes	(3)	(31)
Loss (gain) on foreign currency derivatives	908	(13,735)
Other	692	25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	(10,442)	(15,303)
Other current assets	(13,048)	(4,792)
Other assets	(1,218)	(578)
Accounts payable and other accrued liabilities	(4,313)	(1,300)
Accrued salaries and benefits	(225)	1,782
Other liabilities	4,619	1,701
Net cash provided by continuing operating activities	90,587	29,250
Net cash provided by (used in) discontinued operating activities	554	(11)
Net cash provided by operating activities	91,141	29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired	(286,734)	(10,000)
Cash paid for capital expenditures	(122,035)	(43,323)
Cash paid for real estate acquisitions	(3,428)	(18,326)
Settlement of foreign currency derivatives	(908)
Other	(481)	(439)
Net cash used in investing activities	(413,586)	(72,088)
Financing activities:
Borrowings on long-term debt	875,000	7,500
Borrowings on revolving credit facility	180,000	59,500
Principal payments revolving credit facility	(180,000)	(113,000)
Principal payments on long-term debt	(15,875)	(3,750)
Repayment of assumed CRC debt	(904,467)
Payment of debt issuance costs	(22,775)	(5,810)
Issuance of common stock, net	331,530	374,336
Common stock withheld for minimum statutory taxes, net	(7,826)	(2,981)
Excess tax benefit from equity awards	6,327	3,479
Cash paid for contingent consideration		(3,250)
Other	(150)
Net cash provided by financing activities	261,764	316,024
Effect of exchange rate changes on cash	1,213
Net (decrease) increase in cash and cash equivalents	(59,468)	273,175
Cash and cash equivalents at beginning of the period	94,040	4,569
Cash and cash equivalents at end of the period	34,572	277,744
Effect of acquisitions:
Assets acquired, excluding cash	1,636,164	10,500
Liabilities assumed	(1,009,944)
Issuance of common stock in connection with acquisition	(380,210)	374,336
Deposits paid for acquisitions	40,724
Prior year deposits paid for acquisitions		(500)
Cash paid for acquisitions, net of cash acquired	$ 286,734	$ 10,000

XML

Segment Information (Tables)

6 Months Ended

Jun. 30, 2015

Summary of Reconciliation of Segment EBITDA to Income from Continuing Operations

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Revenue:
U.S. Facilities	$	366,886		$	212,834		$	657,393		$	413,398
U.K. Facilities		84,927			—			158,242			—
Corporate and Other		1,847			969			3,808			1,823
	$	453,660		$	213,803		$	819,443		$	415,221
Segment EBITDA (1):
U.S. Facilities	$	102,342		$	53,031		$	178,706		$	100,563
U.K. Facilities		20,371			—			39,182			—
Corporate and Other		(16,910	)		(8,317	)		(33,373	)		(16,567	)
	$	105,803		$	44,714		$	184,515		$	83,996

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Segment EBITDA (1)	$	105,803		$	44,714		$	184,515		$	83,996
Plus (less):
Equity-based compensation expense		(5,355	)		(2,406	)		(9,249	)		(4,170	)
(Loss) gain on foreign currency derivatives		(961	)		13,735			(908	)		13,735
Transaction-related expenses		(7,157	)		(3,016	)		(25,573	)		(4,595	)
Interest expense, net		(28,049	)		(9,730	)		(50,195	)		(19,437	)
Depreciation and amortization		(14,926	)		(5,935	)		(28,030	)		(11,371	)
Income from continuing operations before income taxes	$	49,355		$	37,362		$	70,560		$	58,158

Summary of Assets by Operating Segment

	June 30, 2015		December 31, 2014
Assets (2):
U.S. Facilities	$	2,729,896	$	1,327,563
U.K. Facilities		944,033		726,693
Corporate and Other		252,456		169,334
	$	3,926,385	$	2,223,590

Goodwill [Member]

Summary of Assets by Operating Segment

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2015	$	693,945	$	109,041		$	—	$	802,986
Increase from 2015 acquisitions		1,103,813		65,293			—		1,169,106
Foreign currency translation		—		6,972			—		6,972
Purchase price allocation and other		281		(33,317	)		—		(33,036	)
Balance at June 30, 2015	$	1,798,039	$	147,989		$	—	$	1,946,028

XML

Acquisitions - 2014 Acquisitions (Detail) $ in Thousands						3 Months Ended		6 Months Ended
	Dec. 31, 2014 USD ($) Beds	Dec. 01, 2014 USD ($) Beds	Sep. 03, 2014 USD ($) Beds	Jul. 01, 2014 USD ($) Beds Facilities	Jan. 01, 2014 USD ($) Beds	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Business Acquisition [Line Items]
Gain on foreign currency derivatives						$ (961)	$ 13,735	$ (908)	$ 13,735
Croxton [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid		$ 15,600
Number of beds | Beds		24
Skyway [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid	$ 300
Number of beds | Beds	28
Acquisition completion date	Dec. 31, 2014
McCallum [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid			$ 37,400
Number of beds | Beds			85
Partnerships In Care [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Acquisition completion date				Jul. 01, 2014
Number of inpatient psychiatric facilities | Facilities				23
Total consideration related to acquisition				$ 661,700
Cash from consideration related to acquisition				12,000
Gain on foreign currency derivatives				$ 15,300
Partnerships In Care [Member] | Minimum [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Number of beds | Beds				1,200
Pacific Grove [Member] | 2014 Acquisitions [Member]
Business Acquisition [Line Items]
Business acquisition cash paid					$ 10,500
Number of beds | Beds					68

XML

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($) $ in Millions		6 Months Ended
	Mar. 12, 2013	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Issued Senior Notes	$ 150.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		Payable semi-annually in arrears on March 15 and September 15 of each year.
Senior notes terms		The Company may redeem the 6.125% Senior Notes at its option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, the Company may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.
Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price percentage		106.125%
Redemption percentage of senior notes		35.00%
Redemption date		Mar. 15, 2016

XML

Subsequent Events - Additional Information (Detail) - Jul. 01, 2015 - Subsequent Event [Member] $ in Millions	USD ($) Beds
United Kingdom [Member]
Subsequent Event [Line Items]
Number of beds | Beds	15
Business acquisition cash paid	$ 5.9
Pennsylvania [Member]
Subsequent Event [Line Items]
Number of beds | Beds	147
Business acquisition cash paid	$ 40.0
Total consideration related to acquisition	35.0
Estimated working capital settlement	$ 5.0

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 34,572	$ 94,040
Accounts receivable, net of allowance for doubtful accounts of $26,233 and $22,449, respectively	182,315	118,378
Deferred tax assets	38,693	20,155
Other current assets	70,325	41,570
Total current assets	325,905	274,143
Property and equipment, net	1,455,390	1,069,700
Goodwill	1,946,028	802,986
Intangible assets, net	58,514	21,636
Deferred tax assets - noncurrent	33,966	13,141
Other assets	106,582	41,984
Total assets	3,926,385	2,223,590
Current liabilities:
Current portion of long-term debt	38,652	26,965
Accounts payable	58,714	48,696
Accrued salaries and benefits	77,545	59,317
Other accrued liabilities	68,197	30,956
Total current liabilities	243,108	165,934
Long-term debt	1,914,555	1,069,305
Deferred tax liabilities - noncurrent	20,200	63,880
Other liabilities	82,218	43,506
Total liabilities	$ 2,260,081	$ 1,342,625
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 90,000,000 shares authorized; 70,596,523 and 59,211,859 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	$ 706	$ 592
Additional paid-in capital	1,567,304	847,301
Accumulated other comprehensive loss	(51,586)	(68,370)
Retained earnings	149,880	101,442
Total equity	1,666,304	880,965
Total liabilities and equity	$ 3,926,385	$ 2,223,590

XML

Acquisitions - Pro Forma Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Business Combinations [Abstract]
Revenue	$ 461,128	$ 431,663	$ 901,582	$ 841,767
Income from continuing operations, before income taxes	$ 51,123	$ 32,289	$ 39,293	$ 31,198

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 33,844	$ 22,451	$ 48,438	$ 35,509
Other comprehensive income:
Foreign currency translation gain	46,173		16,784
Other comprehensive income	46,173		16,784
Comprehensive income	$ 80,017	$ 22,451	$ 65,222	$ 35,509

XML

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding, Beginning balance	737,422	798,809
Options granted	190,900	226,663
Options exercised	(49,045)	(210,199)
Options cancelled	(88,264)	(77,851)
Options outstanding, Ending balance	791,013	737,422	798,809
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 32.19	$ 21.93
Options exercisable, Ending balance	153,900	91,947
Options granted, Weighted Average Exercise Price	$ 62.37	$ 49.80
Options exercised, Weighted Average Exercise Price	23.66	14.93
Options cancelled, Weighted Average Exercise Price	47.86	27.85
Options outstanding, Weighted Average Exercise Price, Ending balance	$ 40.28	$ 32.19	$ 21.93
Options outstanding, Aggregate Intrinsic Value, Beginning balance	$ 14,512	$ 10,700
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 34.84	$ 28.87
Options granted, Aggregate Intrinsic Value	$ 1,148	$ 209
Options granted, Weighted Average Remaining Contractual Term	9 years 8 months 5 days	9 years 3 months
Options exercised, Aggregate Intrinsic Value	$ 5,197	$ 4,994
Options outstanding, Weighted Average Remaining Contractual Term	8 years 1 month 2 days	8 years 1 month 2 days	8 years 2 months 12 days
Options cancelled, Aggregate Intrinsic Value	$ 0	$ 0
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 7 months 6 days	6 years 3 months 18 days
Options outstanding, Aggregate Intrinsic Value, Ending balance	$ 23,104	$ 14,512	$ 10,700
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 6,941	$ 3,326

XML

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Basic and diluted earnings per share:
Income from continuing operations	$ 33,843	$ 22,457	$ 48,435	$ 35,478
Income (loss) from discontinued operations	1	(6)	3	31
Net income	$ 33,844	$ 22,451	$ 48,438	$ 35,509
Denominator:
Weighted average shares outstanding for basic earnings per share	68,296	51,616	65,429	50,872
Effect of dilutive instruments	439	203	353	302
Shares used in computing diluted earnings per common share	68,735	51,819	65,782	51,174
Basic earnings per share:
Income from continuing operations	$ 0.50	$ 0.43	$ 0.74	$ 0.70
Income (loss) from discontinued operations	0	0	0	0
Net income	0.50	0.43	0.74	0.70
Diluted earnings per share:
Income from continuing operations	0.49	0.43	0.74	0.69
Income (loss) from discontinued operations	0	0	0	0
Net income	$ 0.49	$ 0.43	$ 0.74	$ 0.69

XML

Fair Value Measurements - Carrying Amounts and Fair Values of Long-Term Debt and Contingent Consideration Liability (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
12.875% Senior Notes Due 2018 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	$ 96,533	$ 96,420
6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	375,000
9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	24,054	24,274
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	3,000	3,000
Fair Value [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,007,620	525,576
Fair Value [Member] | 12.875% Senior Notes Due 2018 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	106,519	109,688
Fair Value [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	154,500	153,000
Fair Value [Member] | 5.125% Senior Notes due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	297,750	295,500
Fair Value [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	379,688
Fair Value [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	24,054	24,274
Carrying Amounts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration liabilities	3,000	3,000
Carrying Amounts [Member] | Amended and Restated Senior Credit Facility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,007,620	525,576
Carrying Amounts [Member] | 12.875% Senior Notes Due 2018 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	96,533	96,420
Carrying Amounts [Member] | 6.125% Senior Notes Due 2021 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	150,000	150,000
Carrying Amounts [Member] | 5.125% Senior Notes due 2022 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	300,000	300,000
Carrying Amounts [Member] | 5.625% Senior Notes Due 2023 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes	375,000
Carrying Amounts [Member] | 9.0% and 9.5% Revenue Bonds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
9.0% and 9.5% Revenue Bonds	$ 24,054	$ 24,274

XML

Recently Issued Accounting Standards

6 Months Ended

Jun. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Recently Issued Accounting Standards

14. Recently Issued Accounting Standards

In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2015-03, “Interest-Imputation of Interest (Subtopic 835-30)” (“ASU 2015-05”). ASU 2015-03 simplifies the presentation of debt issuance costs by requiring debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, and the new guidance should be applied retrospectively. Management is evaluating the impact of ASU 2015-03 on the Company’s consolidated financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09’s core principal is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Additionally, ASU 2014-09 would permit both public and nonpublic organizations to adopt the new revenue standard early, but not before the original public organization effective date (that is, annual periods beginning after December 15, 2016). Management is evaluating the impact of ASU 2014-09 on the Company’s consolidated financial statements.

XML

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	0.3	0.6	0.9	0.5

XML

Financial Information for the Company and Its Subsidiaries

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

16. Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes and 5.625% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of June 30, 2015 and December 31, 2014, and for the three and six months ended June 30, 2015 and 2014. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

June 30, 2015

(In thousands) 

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	17,179	$	17,393	$	—		$	34,572
Accounts receivable, net		—		160,179		22,136		—			182,315
Deferred tax assets		—		36,502		2,191		—			38,693
Other current assets		—		62,295		8,030		—			70,325
Total current assets		—		276,155		49,750		—			325,905
Property and equipment, net		—		656,262		799,128		—			1,455,390
Goodwill		—		1,700,705		245,323		—			1,946,028
Intangible assets, net		—		55,928		2,586		—			58,514
Deferred tax assets – noncurrent		5,361		16,239		12,366		—			33,966
Investment in subsidiaries		1,332,308		—		—		(1,332,308	)		—
Other assets		389,676		65,957		2,322		(351,373	)		106,582
Total assets	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385
Current liabilities:
Current portion of long-term debt	$	38,437	$	—	$	215	$	—		$	38,652
Accounts payable		—		44,985		13,729		—			58,714
Accrued salaries and benefits		—		65,040		12,505		—			77,545
Other accrued liabilities		22,604		27,543		18,050		—			68,197
Total current liabilities		61,041		137,568		44,499		—			243,108
Long-term debt		—		1,890,716		375,212		(351,373	)		1,914,555
Deferred tax liabilities – noncurrent		—		—		20,200		—			20,200
Other liabilities		—		72,329		9,889		—			82,218
Total liabilities		61,041		2,100,613		449,800		(351,373	)		2,260,081
Total equity		1,666,304		670,633		661,675		(1,332,308	)		1,666,304
Total liabilities and equity	$	1,727,345	$	2,771,246	$	1,111,475	$	(1,683,681	)	$	3,926,385

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2014

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	76,685	$	17,355	$	—		$	94,040
Accounts receivable, net		—		100,797		17,581		—			118,378
Deferred tax assets		—		18,395		1,760		—			20,155
Other current assets		—		36,049		5,521		—			41,570
Total current assets		—		231,926		42,217		—			274,143
Property and equipment, net		—		451,943		617,757		—			1,069,700
Goodwill		—		596,611		206,375		—			802,986
Intangible assets, net		—		19,057		2,579		—			21,636
Deferred tax assets – noncurrent		4,563		—		14,244		(5,666	)		13,141
Investment in subsidiaries		1,759,337		—		—		(1,759,337	)		—
Other assets		202,708		18,727		2,323		(181,774	)		41,984
Total assets	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590
Current liabilities:
Current portion of long-term debt	$	26,750	$	—	$	215	$	—		$	26,965
Accounts payable		—		39,486		9,210		—			48,696
Accrued salaries and benefits		—		47,597		11,720		—			59,317
Other accrued liabilities		13,647		7,688		9,621		—			30,956
Total current liabilities		40,397		94,771		30,766		—			165,934
Long-term debt		1,045,246		—		205,833		(181,774	)		1,069,305
Deferred tax liabilities – noncurrent		—		21,027		48,519		(5,666	)		63,880
Other liabilities		—		33,321		10,185		—			43,506
Total liabilities		1,085,643		149,119		295,303		(187,440	)		1,342,625
Total equity		880,965		1,169,145		590,192		(1,759,337	)		880,965
Total liabilities and equity	$	1,966,608	$	1,318,264	$	885,495	$	(1,946,777	)	$	2,223,590

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	363,851		$	97,947		$	—		$	461,798
Provision for doubtful accounts		—			(7,566	)		(572	)		—			(8,138	)
Revenue		—			356,285			97,375			—			453,660
Salaries, wages and benefits		5,355			183,490			54,457			—			243,302
Professional fees		—			22,579			7,450			—			30,029
Supplies		—			16,929			3,613			—			20,542
Rents and leases		—			7,402			809			—			8,211
Other operating expenses		—			43,145			7,983			—			51,128
Depreciation and amortization		—			10,551			4,375			—			14,926
Interest expense, net		18,106			5,882			4,061			—			28,049
Loss on foreign currency derivatives		961			—			—			—			961
Transaction-related expenses		—			2,946			4,211			—			7,157
Total expenses		24,422			292,924			86,959			—			404,305
(Loss) income from continuing operations before income taxes		(24,422	)		63,361			10,416			—			49,355
Equity in earnings of subsidiaries		50,281			—			—			(50,281	)		—
(Benefit from) provision for income taxes		(7,985	)		20,734			2,763			—			15,512
Income (loss) from continuing operations		33,844			42,627			7,653			(50,281	)		33,843
Income from discontinued operations, net of income taxes		—			1			—			—			1
Net income (loss)	$	33,844		$	42,628		$	7,653		$	(50,281	)	$	33,844
Other comprehensive income:
Foreign currency translation gain		—			—			46,173			—			46,173
Other comprehensive income		—			—			46,173			—			46,173
Comprehensive income (loss)	$	33,844		$	42,628		$	53,826		$	(50,281	)	$	80,017

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Three Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	207,143		$	13,521		$	—		$	220,664
Provision for doubtful accounts		—			(5,954	)		(907	)		—			(6,861	)
Revenue		—			201,189			12,614			—			213,803
Salaries, wages and benefits		2,406			114,976			5,091			—			122,473
Professional fees		—			9,691			1,200			—			10,891
Supplies		—			9,967			629			—			10,596
Rents and leases		—			2,613			276			—			2,889
Other operating expenses		—			22,522			2,124			—			24,646
Depreciation and amortization		—			5,581			354			—			5,935
Interest expense, net		9,202			—			528			—			9,730
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			3,016			—			—			3,016
Total expenses		(2,127	)		168,366			10,202			—			176,441
Income from continuing operations before income taxes		2,127			32,823			2,412			—			37,362
Equity in earnings of subsidiaries		20,972			—			—			(20,972	)		—
Provision for income taxes		648			13,315			942			—			14,905
Income (loss) from continuing operations		22,451			19,508			1,470			(20,972	)		22,457
Loss from discontinued operations, net of income taxes		—			(6	)		—			—			(6	)
Net income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451
Comprehensive income (loss)	$	22,451		$	19,502		$	1,470		$	(20,972	)	$	22,451

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	651,616		$	184,340		$	—		$	835,956
Provision for doubtful accounts		—			(14,985	)		(1,528	)		—			(16,513	)
Revenue		—			636,631			182,812			—			819,443
Salaries, wages and benefits		9,249			339,189			100,735			—			449,173
Professional fees		—			39,064			13,392			—			52,456
Supplies		—			29,938			6,858			—			36,796
Rents and leases		—			12,519			1,578			—			14,097
Other operating expenses		—			75,392			16,263			—			91,655
Depreciation and amortization		—			19,262			8,768			—			28,030
Interest expense, net		31,054			11,603			7,538			—			50,195
Loss on foreign currency derivatives		908			—			—			—			908
Transaction-related expenses		—			21,362			4,211			—			25,573
Total expenses		41,211			548,329			159,343			—			748,883
(Loss) income from continuing operations before income taxes		(41,211	)		88,302			23,469			—			70,560
Equity in earnings of subsidiaries		76,268			—			—			(76,268	)		—
(Benefit from) provision for income taxes		(13,381	)		29,251			6,255			—			22,125
Income (loss) from continuing operations		48,438			59,051			17,214			(76,268	)		48,435
Income from discontinued operations, net of income taxes		—			3			—			—			3
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Other comprehensive income:
Foreign currency translation gain		—			—			16,784			—			16,784
Other comprehensive income		—			—			16,784			—			16,784
Comprehensive income (loss)	$	48,438		$	59,054		$	33,998		$	(76,268	)	$	65,222

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue before provision for doubtful accounts	$	—		$	400,425		$	26,358		$	—		$	426,783
Provision for doubtful accounts		—			(10,464	)		(1,098	)		—			(11,562	)
Revenue		—			389,961			25,260			—			415,221
Salaries, wages and benefits		4,170			225,629			10,249			—			240,048
Professional fees		—			18,944			2,329			—			21,273
Supplies		—			19,353			1,307			—			20,660
Rents and leases		—			5,108			550			—			5,658
Other operating expenses		—			43,600			4,156			—			47,756
Depreciation and amortization		—			10,666			705			—			11,371
Interest expense, net		18,313			—			1,124			—			19,437
Loss (gain) on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Transaction-related expenses		—			4,595			—			—			4,595
Total expenses		8,748			327,895			20,420			—			357,063
(Loss) income from continuing operations before income taxes		(8,748	)		62,066			4,840			—			58,158
Equity in earnings of subsidiaries		40,839			—			—			(40,839	)		—
(Benefit from) provision for income taxes		(3,418	)		24,249			1,849			—			22,680
Income (loss) from continuing operations		35,509			37,817			2,991			(40,839	)		35,478
Income from discontinued operations, net of income taxes		—			31			—			—			31
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Comprehensive income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2015

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	48,438		$	59,054		$	17,214		$	(76,268	)	$	48,438
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(76,268	)		—			—			76,268			—
Depreciation and amortization		—			19,262			8,768			—			28,030
Amortization of debt issuance costs		—			3,438			(220	)		—			3,218
Equity-based compensation expense		9,249			—			—			—			9,249
Deferred income tax (benefit) expense		(798	)		22,964			2,516			—			24,682
Loss from discontinued operations, net of taxes		—			(3	)		—			—			(3	)
Loss (gain) on foreign currency derivatives		908			—			—			—			908
Other		—			662			30			—			692
Change in operating assets and liabilities, net of effect of acquisitions:											—
Accounts receivable, net		—			(11,409	)		967			—			(10,442	)
Other current assets		—			(12,026	)		(1,022	)		—			(13,048	)
Other assets		(300	)		(1,220	)		2			300			(1,218	)
Accounts payable and other accrued liabilities		—			5,991			(10,304	)		—			(4,313	)
Accrued salaries and benefits		—			791			(1,016	)		—			(225	)
Other liabilities		—			5,442			(823	)		—			4,619
Net cash (used in) provided by continuing operating activities		(18,771	)		92,946			16,112			300			90,587
Net cash provided by discontinued operating activities		—			554			—			—			554
Net cash (used in) provided by operating activities		(18,771	)		93,500			16,112			300			91,141
Investing activities:											—
Cash paid for acquisitions, net of cash acquired		—			(89,041	)		(197,693	)		—			(286,734	)
Cash paid for capital expenditures		—			(62,101	)		(59,934	)		—			(122,035	)
Cash paid for real estate acquisitions		—			(3,428	)		—			—			(3,428	)
Settlement of foreign currency derivatives		—			(908	)		—			—			(908	)
Other		—			(481	)		—			—			(481	)
Net cash used in investing activities		—			(155,959	)		(257,627	)		—			(413,586	)
Financing activities:											—
Borrowings on long-term debt		875,000			—			—			—			875,000
Borrowings on revolving credit facility		180,000			—			—			—			180,000
Principal payments on revolving credit facility		(180,000	)		—			—			—			(180,000	)
Repayment of assumed CRC debt		(904,467	)		—			—			—			(904,467	)
Principal payments on long-term debt		(15,875	)		—			(300	)		300			(15,875	)
Payment of debt issuance costs		—			(22,775	)		—			—			(22,775	)
Issuance of Common Stock		—			331,530			—			—			331,530
Common stock withheld for minimum statutory taxes, net		—			(7,826	)		—			—			(7,826	)
Excess tax benefit from equity awards		—			6,327			—			—			6,327
Other		—			(150	)		—			—			(150	)
Cash provided by (used in) intercompany activity		64,113			(305,366	)		241,853			(600	)		—
Net cash provided by (used in) financing activities		18,771			1,740			241,553			(300	)		261,764
Effect of exchange rate changes on cash		—			1,213			—			—			1,213
Net (decrease) increase in cash and cash equivalents		—			(59,506	)		38			—			(59,468	)
Cash and cash equivalents at beginning of the period		—			76,685			17,355			—			94,040
Cash and cash equivalents at end of the period	$	—		$	17,179		$	17,393		$	—		$	34,572

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Six Months Ended June 30, 2014

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	35,509		$	37,848		$	2,991		$	(40,839	)	$	35,509
Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:
Equity in earnings of subsidiaries		(40,839	)		—			—			40,839			—
Depreciation and amortization		—			10,666			705			—			11,371
Amortization of debt issuance costs		1,560			—			(226	)		—			1,334
Equity-based compensation expense		4,170			—			—			—			4,170
Deferred income tax expense		5,585			3,105			407			—			9,097
Income from discontinued operations, net of taxes		—			(31	)		—			—			(31	)
Gain on foreign currency derivatives		(13,735	)		—			—			—			(13,735	)
Other		—			25			—			—			25
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net		—			(16,670	)		1,367			—			(15,303	)
Other current assets		—			(5,033	)		241			—			(4,792	)
Other assets		165			(578	)		—			(165	)		(578	)
Accounts payable and other accrued liabilities		—			(1,584	)		284			—			(1,300	)
Accrued salaries and benefits		—			1,701			81			—			1,782
Other liabilities		—			1,701			—			—			1,701
Net cash (used in) provided by continuing operating activities		(7,585	)		31,150			5,850			(165	)		29,250
Net cash used in discontinued operating activities		—			(11	)		—			—			(11	)
Net cash (used in) provided by operating activities		(7,585	)		31,139			5,850			(165	)		29,239
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(10,000	)		—			—			(10,000	)
Cash paid for capital expenditures		—			(39,782	)		(3,541	)		—			(43,323	)
Cash paid for real estate acquisitions		—			(18,326	)		—			—			(18,326	)
Other		—			(439	)		—			—			(439	)
Net cash used in investing activities		—			(68,547	)		(3,541	)		—			(72,088	)
Financing activities:
Borrowings on long-term debt		7,500			—			—			—			7,500
Borrowings on revolving credit facility		59,500			—			—			—			59,500
Principal payments on revolving credit facility		(113,000	)		—			—			—			(113,000	)
Principal payments on long-term debt		(3,750	)		—			(165	)		165			(3,750	)
Payment of debt issuance costs		(5,810	)		—			—			—			(5,810	)
Issuance of common stock, net		374,336			—			—			—			374,336
Common stock withheld for minimum statutory taxes, net		(2,981	)		—			—			—			(2,981	)
Excess tax benefit from equity awards		3,479			—			—			—			3,479
Cash paid for contingent consideration		—			(3,250	)		—			—			(3,250	)
Cash (used in) provided by intercompany activity		(311,689	)		315,175			(5,411	)		1,925			—
Net cash provided by (used in) financing activities		7,585			311,925			(5,576	)		2,090			316,024
Net increase (decrease) in cash and cash equivalents		—			274,517			(3,267	)		1,925			273,175
Cash and cash equivalents at beginning of the period		—			—			6,494			(1,925	)		4,569
Cash and cash equivalents at end of the period	$	—		$	274,517		$	3,227		$	—		$	277,744

XML

Segment Information - Summary of Financial Information by Operating Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 453,660	$ 213,803	$ 819,443	$ 415,221
Segment EBITDA	105,803	44,714	184,515	83,996
Equity-based compensation expense	(5,355)	(2,406)	(9,249)	(4,170)
(Loss) gain on foreign currency derivatives	(961)	13,735	(908)	13,735
Transaction-related expenses	(7,157)	(3,016)	(25,573)	(4,595)
Interest expense, net	(28,049)	(9,730)	(50,195)	(19,437)
Depreciation and amortization	(14,926)	(5,935)	(28,030)	(11,371)
Income from continuing operations before income taxes	49,355	37,362	70,560	58,158
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	366,886	212,834	657,393	413,398
Segment EBITDA	102,342	53,031	178,706	100,563
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	84,927		158,242
Segment EBITDA	20,371		39,182
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Revenue	1,847	969	3,808	1,823
Segment EBITDA	$ (16,910)	$ (8,317)	$ (33,373)	$ (16,567)

XML

Condensed Consolidated Statement of Equity (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Loss [Member]	Retained Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2014	$ 880,965	$ 592	$ 847,301	$ (68,370)	$ 101,442
Balance, shares at Dec. 31, 2014	59,211,859	59,212
Common stock issued under stock incentive plans		$ 2	(2)
Common stock issued under stock incentive plans, shares	49,045	234,000
Common stock withheld for minimum statutory taxes	$ (7,826)		(7,826)
Equity-based compensation expense	9,249		9,249
Excess tax benefit from equity awards	6,327		6,327
Issuance of common stock, net	711,740	$ 112	711,628
Issuance of common stock, net, shares		11,150,000
Other comprehensive loss	16,784			16,784
Other	627		627
Net income	48,438				48,438
Balance at Jun. 30, 2015	$ 1,666,304	$ 706	$ 1,567,304	$ (51,586)	$ 149,880
Balance, shares at Jun. 30, 2015	70,596,523	70,596

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Receivable, allowance for doubtful accounts	$ 26,233	$ 22,449
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	70,596,523	59,211,859
Common stock, shares outstanding	70,596,523	59,211,859

XML

Income Taxes

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

The provision for income taxes for continuing operations for the three months ended June 30, 2015 and 2014 reflects effective tax rates of 31.4% and 39.9%, respectively. The provision for income taxes for continuing operations for the six months ended June 30, 2015 and 2014 reflects effective tax rates of 31.4% and 39.0%, respectively. The decrease in the tax rate for the three and six months ended June 30, 2015 was primarily attributable to the acquisition of Partnerships in Care, which is located in a lower taxing jurisdiction and for which earnings are permanently reinvested.

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 05, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		71,637,097

XML

Derivatives

6 Months Ended

Jun. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives

10. Derivatives

The Company entered into foreign currency forward contracts during the three and six months ended June 30, 2015 and 2014 in connection with acquisitions in the United Kingdom. The foreign currency forward contracts limited the economic risk of changes in the foreign exchange rate between US Dollars (“USD”) and British Pounds (“GBP”) associated with the payment of the purchase price in GBP in April 2015 and July 2014. These foreign currency forward contracts did not meet the hedge accounting criteria under Accounting Standards Codification 815, Derivatives and Hedging. As such, losses associated with changes in fair value of $1.0 million and $0.9 million for the three and six months ended June 30, 2015, respectively, have been recorded in the consolidated statements of income. The final fair value of the 2015 foreign currency forward contracts settled during the three and six months ended June 30, 2015. Gains associated with changes in fair value of $13.7 million for the three and six months ended June 30, 2014 have been recorded in the consolidated statements of income. The final fair value of the 2014 foreign currency forward contracts settled on July 1, 2014 for $15.3 million in connection with the acquisition of Partnerships in Care.

XML

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue before provision for doubtful accounts	$ 461,798	$ 220,664	$ 835,956	$ 426,783
Provision for doubtful accounts	(8,138)	(6,861)	(16,513)	(11,562)
Revenue	453,660	213,803	819,443	415,221
Salaries, wages and benefits (including equity-based compensation expense of $5,355, $2,406, $9,249 and $4,170, respectively)	243,302	122,473	449,173	240,048
Professional fees	30,029	10,891	52,456	21,273
Supplies	20,542	10,596	36,796	20,660
Rents and leases	8,211	2,889	14,097	5,658
Other operating expenses	51,128	24,646	91,655	47,756
Depreciation and amortization	14,926	5,935	28,030	11,371
Interest expense, net	28,049	9,730	50,195	19,437
Loss (gain) on foreign currency derivatives	961	(13,735)	908	(13,735)
Transaction-related expenses	7,157	3,016	25,573	4,595
Total expenses	404,305	176,441	748,883	357,063
Income from continuing operations before income taxes	49,355	37,362	70,560	58,158
Provision for income taxes	15,512	14,905	22,125	22,680
Income (loss) from continuing operations	33,843	22,457	48,435	35,478
Income (loss) from discontinued operations, net of income taxes	1	(6)	3	31
Net income	$ 33,844	$ 22,451	$ 48,438	$ 35,509
Basic earnings per share:
Income from continuing operations	$ 0.50	$ 0.43	$ 0.74	$ 0.70
Income (loss) from discontinued operations	0	0	0	0
Net income	0.50	0.43	0.74	0.70
Diluted earnings per share:
Income from continuing operations	0.49	0.43	0.74	0.69
Income (loss) from discontinued operations	0	0	0	0
Net income	$ 0.49	$ 0.43	$ 0.74	$ 0.69
Weighted-average shares outstanding:
Basic	68,296	51,616	65,429	50,872
Diluted	68,735	51,819	65,782	51,174

XML

Other Intangible Assets

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Other Intangible Assets

4. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2015		December 31, 2014		June 30, 2015			December 31, 2014
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(1,540	)	$	(1,330	)
Non-compete agreements		1,247		1,247		(1,205	)		(1,155	)
		3,347		3,347		(2,745	)		(2,485	)
Intangible assets not subject to amortization:
Licenses and accreditations		10,318		9,184		—			—
Trade names		37,800		3,000		—			—
Certificates of need		9,794		8,590		—			—
		57,912		20,774		—			—
Total	$	61,259	$	24,121	$	(2,745	)	$	(2,485	)

In connection with the CRC acquisition, the Company acquired license and accreditation intangible assets with a fair value of $1.1 million, trade name intangible assets with a fair value of $34.8 million and certificate of need intangible assets with a fair value of $1.1 million.

Amortization expense related to definite-lived intangible assets was $0.1 million for both the three months ended June 30, 2015 and 2014, respectively, and $0.3 million for both the six months ended June 30, 2015 and 2014, respectively. Estimated amortization expense for the years ending December 31, 2015, 2016, 2017, 2018 and 2019 is $0.5 million, $0.4 million, $0, $0 and $0, respectively. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

XML

Acquisitions

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Acquisitions

3. Acquisitions

UK Acquisitions

On June 1, 2015, the Company completed the acquisitions of (i) one facility from Choice for approximately $25.9 million and (ii) 15 facilities from Care UK Limited (“Care UK”) for approximately $88.3 million. The inpatient psychiatric facility acquired from Choice has 42 beds and is located in England. The inpatient psychiatric facilities acquired from Care UK have an aggregate of 299 beds and are located in England.

On April 1, 2015, the Company completed the acquisitions of (i) two facilities from Choice Lifestyles (“Choice”) for approximately $37.5 million, (ii) Pastoral Care Group (“Pastoral”) for approximately $34.2 million and (iii) Mildmay Oaks f/k/a Vista Independent Hospital (“Mildmay Oaks”) for approximately $14.9 million. The two inpatient psychiatric facilities acquired from Choice have an aggregate of 48 beds and are located in England. Pastoral operates two inpatient psychiatric facilities with an aggregate of 65 beds located in Wales. Mildmay Oaks is an inpatient psychiatric facility with 67 beds located in England.

QAM

On March 1, 2015, the Company acquired the stock of Quality Addiction Management, Inc. (“QAM”) for total consideration of approximately $54.6 million. QAM operates seven comprehensive treatment centers located in Wisconsin.

CRC

On February 11, 2015, the Company completed its acquisition of CRC Health Group, Inc. (“CRC”) for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness of $904.5 million. CRC is a leading provider of treatment services related to substance abuse and other addiction and behavioral disorders. At the acquisition date, CRC operated 35 inpatient facilities with over 2,400 beds and 81 comprehensive treatment centers located in 30 states.

2014 Acquisitions

On December 1, 2014, the Company acquired the assets of Croxton Warwick Lodge (“Croxton”), an inpatient psychiatric facility with 24 beds located in Melton Mowbray, Leicestershire, England, for cash consideration of $15.6 million. On December 31, 2014, the Company completed the acquisition of Skyway House (“Skyway”), a substance abuse facility with 28 beds located in Chico, California, for cash consideration of $0.3 million. On September 3, 2014, the Company completed the acquisition of McCallum Place (“McCallum”), an eating disorder treatment facility with 85 beds offering residential, partial hospitalization and intensive outpatient treatment programs located in St. Louis, Missouri, and Austin, Texas, for total consideration of $37.4 million. On July 1, 2014, the Company acquired Partnerships in Care for cash consideration of $661.7 million, which was net of cash acquired of $12.0 million and the gain on settlement of foreign currency derivatives of $15.3 million. At the acquisition date, Partnerships in Care was the second largest independent provider of inpatient behavioral healthcare services in the United Kingdom, operating 23 inpatient behavioral healthcare facilities with over 1,200 beds. On January 1, 2014, the Company acquired the assets of Pacific Grove Hospital (“Pacific Grove”), an inpatient psychiatric facility with 68 beds located in Riverside, California, for cash consideration of $10.5 million.

Summary of Acquisitions

The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $175.5 million of the goodwill associated with domestic acquisitions completed in 2015 and 2014 is deductible for federal income tax purposes. The fair values assigned to certain assets and liabilities assumed by the Company have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. Specifically, the Company is further assessing the valuation of certain tax matters as well as certain receivables and assumed liabilities of Choice, Care UK, Pastoral, Mildmay Oaks, QAM, CRC and McCallum, the valuation of real property and intangible assets of Choice, Pastoral, Mildmay Oaks, Care UK, QAM and CRC and the valuation of certain tax matters of Partnerships in Care.

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the six months ended June 30, 2015 in connection with the 2015 acquisitions were as follows (in thousands):

	CRC		Other		Total
Cash	$	19,600	$	4,468	$	24,068
Accounts receivable		47,095		6,130		53,225
Prepaid expenses and other current assets		25,522		1,380		26,902
Property and equipment		140,152		138,613		278,765
Goodwill		1,050,620		118,486		1,169,106
Intangible assets		37,000		—		37,000
Deferred tax assets – noncurrent		64,688		—		64,688
Other assets		6,478		—		6,478
Total assets acquired		1,391,155		269,077		1,660,232
Accounts payable		5,301		7,114		12,415
Accrued salaries and benefits		14,860		1,642		16,502
Other accrued expenses		38,703		2,546		41,249
Deferred tax liabilities – noncurrent		—		1,052		1,052
Long-term debt		904,467		—		904,467
Other liabilities		34,248		11		34,259
Total liabilities assumed		997,579		12,365		1,009,944
Net assets acquired	$	393,576	$	256,712	$	650,288

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2014 in connection with the 2014 acquisitions were as follows (in thousands):

	Partnerships in Care		Other		Total
Cash	$	11,674	$	—	$	11,674
Accounts receivable		7,684		1,849		9,533
Prepaid expenses and other current assets		8,828		169		8,997
Property and equipment		610,477		27,203		637,680
Goodwill		87,047		32,232		119,279
Intangible assets		651		204		855
Other assets		7,037		3,240		10,277
Total assets acquired		733,398		64,897		798,295
Accounts payable		3,958		93		4,051
Accrued salaries and benefits		10,422		—		10,422
Other accrued expenses		7,166		1,014		8,180
Deferred tax liabilities – noncurrent		15,597		—		15,597
Other liabilities		7,704		—		7,704
Total liabilities assumed		44,847		1,107		45,954
Net assets acquired	$	688,551	$	63,790	$	752,341

Other

The qualitative factors comprising the goodwill acquired in the Pacific Grove, Partnerships in Care, McCallum, Croxton, Skyway, CRC, QAM, Choice, Pastoral, Mildmay Oaks and Care UK acquisitions (collectively the “2014 and 2015 Acquisitions”) include efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance, and applying best practices throughout the combined companies.

Transaction-related expenses comprised the following costs for the three and six months ended June 30, 2015 and 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Advisory and financing commitment fees	$	—	$	—	$	10,337	$	—
Legal, accounting and other costs		5,234		3,016		9,054		4,136
Severance and contract termination costs		1,923		—		6,182		459
	$	7,157	$	3,016	$	25,573	$	4,595

Pro Forma Information

The condensed consolidated statements of income for the three and six months ended June 30, 2015 include revenue of $222.1 million and $369.7 million, respectively, and income from continuing operations before income taxes of $37.6 million and $58.1 million, respectively, related to the 2014 and 2015 Acquisitions. The condensed consolidated statements of income for the three and six months ended June 30, 2014 include revenue of $1.6 million and $2.9 million, respectively, and income from continuing operations before income taxes of $0.1 million and loss from continuing operations before income taxes of $0.1 million, respectively, related to acquisitions completed in 2014.

The following table provides certain pro forma financial information for the Company as if the 2014 and 2015 Acquisitions occurred as of January 1, 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Revenue	$	461,128	$	431,663	$	901,582	$	841,767
Income from continuing operations, before income taxes	$	51,123	$	32,289	$	39,293	$	31,198

XML

Subsequent Events

6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

15. Subsequent Events

On July 1, 2015, the Company completed the acquisition of (i) the assets of Belmont Behavioral Health, an inpatient psychiatric facility with 147 beds located in Philadelphia, Pennsylvania for cash consideration of approximately $40.0 million which consists of $35.0 million base purchase price and an estimated working capital settlement of $5.0 million, and (ii) The Manor Clinic, a substance abuse facility with 15 beds located in England, for cash consideration of approximately $5.9 million.

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

11. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 9.0% and 9.5% Revenue Bonds and contingent consideration liabilities as of June 30, 2015 and December 31, 2014 were as follows (in thousands):

	Carrying Amount				Fair Value
	June 30, 2015		December 31, 2014		June 30, 2015		December 31, 2014
Amended and Restated Senior Credit Facility	$	1,007,620	$	525,576	$	1,007,620	$	525,576
12.875% Senior Notes due 2018	$	96,533	$	96,420	$	106,519	$	109,688
6.125% Senior Notes due 2021	$	150,000	$	150,000	$	154,500	$	153,000
5.125% Senior Notes due 2022	$	300,000	$	300,000	$	297,750	$	295,500
5.625% Senior Notes due 2023	$	375,000		—	$	379,688		—
9.0% and 9.5% Revenue Bonds	$	24,054	$	24,274	$	24,054	$	24,274
Contingent consideration liabilities	$	3,000	$	3,000	$	3,000	$	3,000

The Company’s Amended and Restated Senior Credit Facility, 12.875% Senior Notes, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 9.0% and 9.5% Revenue Bonds were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate. Significant increases with respect to assumptions as to future earnings and probabilities of achieving such future earnings would result in higher fair value measurement while an increase in the discount rate would result in a lower fair value measurement. During the six months ended June 30, 2014, the Company changed its projections of the timing of future payments of the contingent consideration liability related to the acquisition of The Pavilion at Healthpark LLC (“Park Royal”). This change resulted in a $0.5 million increase in the fair value of the contingent consideration liability, which was recorded in transaction-related expenses in the consolidated statements of income. During the year ended December 31, 2014, the Company paid $5.0 million of the estimated $7.0 million Park Royal contingent consideration liability as a result of the facility achieving certain earnings targets. In addition to the Park Royal contingent consideration liability, the Company may make an earn-out payment of up to $6.0 million to the former owners of McCallum, contingent upon achievement by McCallum of certain operating performance targets for the one-year period ending December 31, 2015.

XML

Equity Offerings

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

Equity Offerings

7. Equity Offerings

On June 17, 2014, the Company completed the offering of 8,881,794 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $44.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.6 million and additional offering-related costs of $0.8 million, were $374.4 million. The Company used the net offering proceeds to fund a portion of the consideration for the acquisition of Partnerships in Care.

On February 11, 2015, the Company completed its acquisition of CRC for total consideration of approximately $1.3 billion. As consideration for the acquisition, the Company issued 5,975,326 shares of its common stock to certain holders of CRC common stock and repaid CRC’s outstanding indebtedness.

On May 11, 2015, the Company completed the offering of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $66.50 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.6 million, were $331.5 million. The Company used the net offering proceeds to repay outstanding indebtedness and fund acquisitions.

XML

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	722,028	461,697
Granted, Number of Shares	480,152	468,484
Cancelled, Number of Shares	(55,674)	(75,369)
Vested, Number of Shares	(107,263)	(132,784)
Unvested, Number of Shares/Units, Ending balance	1,039,243	722,028
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 39.77	$ 24.96
Granted, Weighted Average Grant-Date Fair Value	62.08	48.99
Cancelled, Weighted Average Grant-Date Fair Value	49.59	36.36
Vested, Weighted Average Grant-Date Fair Value	32.47	22.81
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 51.03	$ 39.77

XML

Property and Equipment

6 Months Ended

Jun. 30, 2015

Text Block [Abstract]

Property and Equipment

5. Property and Equipment

Property and equipment consists of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	June 30, 2015			December 31, 2014
Land	$	201,362		$	132,406
Building and improvements		1,102,767			858,055
Equipment		118,736			73,584
Construction in progress		117,930			66,268
		1,540,795			1,130,313
Less accumulated depreciation		(85,405	)		(60,613	)
Property and equipment, net	$	1,455,390		$	1,069,700

XML

Long-Term Debt

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Long-Term Debt

6. Long-Term Debt

Long-term debt consisted of the following (in thousands):

	June 30, 2015			December 31, 2014
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loans (net of discount of $1,628 and $1,924, respectively)	$	512,497		$	525,576
Senior Secured Term B Loans (net of discount of $2,377)		495,123			—
Senior Secured Revolving Line of Credit		—			—
12.875% Senior Notes due 2018 (net of discount of $967 and $1,080, respectively)		96,533			96,420
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		375,000			—
9.0% and 9.5% Revenue Bonds (net of premium of $1,429 and $1,649, respectively)		24,054			24,274
		1,953,207			1,096,270
Less: current portion		(38,652	)		(26,965	)
Long-term debt	$	1,914,555		$	1,069,305

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (“Amended and Restated Senior Credit Facility”).

On February 13, 2014, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Credit Agreement, to increase the size of the Amended and Restated Senior Credit Facility and extend the maturity date thereof, which resulted in the Company having a revolving line of credit of up to $300.0 million and term loans of $300.0 million. The Fourth Amendment also reduced the interest rates applicable to the Amended and Restated Senior Credit Facility and provided increased flexibility to the Company in terms of the financial and other restrictive covenants. The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.

On June 16, 2014, the Company entered into a Fifth Amendment (the “Fifth Amendment”) to the Amended and Restated Credit Agreement. The Fifth Amendment specifically permitted the Company’s acquisition of Partnerships in Care, gave the Company the ability to incur a tranche of term loan B debt in the future through its incremental credit facility, and modified certain of the restrictive covenants on miscellaneous investments and incurrence of miscellaneous liens. The restrictive covenants on investments in joint ventures and foreign subsidiaries were also amended such that the Company may now invest, in any given fiscal year, up to five percent (5%) of its total assets in both joint ventures and foreign subsidiaries, respectively; provided that the aggregate amount of investments in both joint ventures and foreign subsidiaries, respectively, may not exceed ten percent (10%) of its total assets over the life of the Amended and Restated Senior Credit Facility; provided further that the aggregate amount of investments made in both joint ventures and foreign subsidiaries collectively pursuant to the foregoing may not exceed fifteen percent (15%) of its total assets. Finally, the Fifth Amendment provided increased flexibility to the Company in terms of its financial covenants.

On December 15, 2014, the Company entered into a Sixth Amendment (the “Sixth Amendment”) to our Amended and Restated Credit Agreement. Pursuant to the Sixth Amendment, we incurred $235.0 million of additional term loans. A portion of the additional term loan advance was used to prepay our outstanding revolving loans, and a portion of the additional term loan advance is being held as cash on the consolidated balance sheet. The Sixth Amendment also specifically permitted the acquisition of CRC. In connection with the acquisition of CRC, the Sixth Amendment (i) imposed a temporary reserve on the Company’s revolving credit facility in the amount of $110.0 million in order to preserve such reserved amounts for later borrowings to partially fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) (the reserve is no longer in effect due to the acquisition of CRC), (ii) permitted the incurrence of an additional incremental term loan facility under the Amended and Restated Credit Agreement partially to fund the consideration for the acquisition of CRC (subject to limited conditionality provisions) and (iii) permitted the issuance of additional senior unsecured indebtedness or senior unsecured bridge indebtedness partially to fund the consideration for the acquisition of CRC.

On February 6, 2015, the Company entered into a Seventh Amendment (the “Seventh Amendment”) to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreement in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.

On February 11, 2015, the Company entered into a First Incremental Facility Amendment (the “First Incremental Amendment”) to our Amended and Restated Credit Agreement. The First Incremental Amendment activated a new $500.0 million incremental Term Loan B facility (the “TLB Facility”) that was added to our Amended and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the TLB Facility were used to fund a portion of the purchase price for the acquisition of CRC.

On April 22, 2015, the Company entered into an Eighth Amendment (the “Eighth Amendment”) to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

The Company had $291.1 million of availability under the revolving line of credit as of June 30, 2015. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our outstanding term loan A loans (“TLA Facility”) of $6.7 million for June 30, 2015 to December 31, 2015, $10.0 million for March 31, 2016 to December 31, 2016, $13.4 million for March 31, 2017 to December 31, 2017, and $16.7 million for March 31, 2018 to December 31, 2018, with the remaining principal balance of the TLA Facility due on the maturity date of February 13, 2019. On December 15, 2014, prior to the execution of the Sixth Amendment, the Company prepaid the December 31, 2014 quarterly term loan principal payment of $1.9 million. The Company is required to repay the TLB Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TLB Facility due on February 11, 2022.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 3.25% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 2.25% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at June 30, 2015. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of June 30, 2015, the Pro Rata Facilities bore interest at a rate of LIBOR plus 3.25%. In addition, we are required to pay a commitment fee on undrawn amounts under the revolving line of credit. We paid a commitment fee of 0.50% for undrawn amounts for the period from January 1, 2013 through February 12, 2014 and 0.40% for undrawn amounts for the period from February 13, 2014 through June 30, 2015. Borrowings under the Pro Rata Facilities mature on February 13, 2019.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of June 30, 2015, the Company was in compliance with such covenants.

12.875% Senior Notes due 2018

On November 1, 2011, the Company issued $150.0 million of 12.875% Senior Notes due 2018 (the “12.875% Senior Notes”) at 98.323% of the aggregate principal amount of $150.0 million, a discount of $2.5 million. The notes bear interest at a rate of 12.875% per annum. The Company pays interest on the notes semi-annually, in arrears, on November 1 and May 1 of each year.

The indenture governing the 12.875% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 12.875% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

On March 12, 2013, the Company redeemed $52.5 million in principal amount of the 12.875% Senior Notes using a portion of the net proceeds of its December 2012 equity offering pursuant to the provision in the indenture permitting an optional redemption with equity proceeds of up to 35% of the principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were redeemed at a redemption price of 112.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date in accordance with the provisions of the indenture governing the 12.875% Senior Notes. As part of the redemption of 35% of the 12.875% Senior Notes, the Company recorded a debt extinguishment charge of $9.4 million, including the premium and write-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

The indenture governing the 6.125% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The 6.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 6.125% Senior Notes at its option, in whole or part, at any time prior to March 15, 2016, at a price equal to 100% of the principal amount of the 6.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 6.125% Senior Notes, in whole or in part, on or after March 15, 2016, at the redemption prices set forth in the indenture governing the 6.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before March 15, 2016, the Company may elect to redeem up to 35% of the aggregate principal amount of the 6.125% Senior Notes at a redemption price equal to 106.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, beginning on January 1, 2015.

The indenture governing the 5.125% Senior Notes contains covenants that limit, among other things, the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.125% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.125% Senior Notes at its option, in whole or part, at any time prior to July 1, 2017, at a price equal to 100% of the principal amount of the 5.125% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. The Company may redeem the 5.125% Senior Notes, in whole or in part, on or after July 1, 2017, at the redemption prices set forth in the indenture governing the 5.125% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before July 1, 2017, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.125% Senior Notes at a redemption price equal to 105.125% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2015.

The indenture governing the 5.625% Senior Notes contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets and (vii) create liens on assets.

The 5.625% Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the 5.625% Senior Notes at its option, in whole or part, at any time prior to February 15, 2018, at a price equal to 100% of the principal amount of the 5.625% Senior Notes redeemed, plus accrued and unpaid interest to the redemption date and plus an applicable premium. We may redeem the 5.625% Senior Notes, in whole or in part, on or after February 15, 2018, at the redemption prices set forth in the indenture governing the 5.625% Senior Notes plus accrued and unpaid interest to the redemption date. At any time on or before February 15, 2018, the Company may elect to redeem up to 35% of the aggregate principal amount of the 5.625% Senior Notes at a redemption price equal to 105.625% of the principal amount thereof, plus accrued and unpaid interest to the redemption date, with the net proceeds of one or more equity offerings.

9.0% and 9.5% Revenue Bonds

On November 11, 2012, in connection with the acquisition of Park Royal, the Company assumed debt of $23.0 million. The fair market value of the debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bonds in the amount of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of June 30, 2015 and December 31, 2014, $2.3 million was recorded within other assets on the balance sheet related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.

XML

Equity-Based Compensation

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity-Based Compensation

8. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As of June 30, 2015, a maximum of 4,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 1,257,326 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the date of grant.

The Company recognized $5.4 million and $2.4 million in equity-based compensation expense for the three months ended June 30, 2015 and 2014, respectively, and $9.2 million and $4.2 million for the six months ended June 30, 2015 and 2014, respectively. As of June 30, 2015, there was $57.7 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.6 years. As of June 30, 2015, there were no warrants outstanding. The Company recognized a deferred income tax benefit of $2.2 million and $1.0 million for the three months ended June 30, 2015 and 2014, respectively, related to equity-based compensation expense. The Company recognized a deferred income tax benefit of $3.8 million and $1.7 million for the six months ended June 30, 2015 and 2014, respectively, related to equity-based compensation expense. The actual tax benefit realized from stock options exercised during the three months ended June 30, 2015 and 2014 was $2.0 million and $0.8 million, respectively. The actual tax benefit realized from stock options exercised during the six months ended June 30, 2015 and 2014 was $6.3 million and $3.5 million, respectively.

Stock option activity during 2014 and 2015 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2014		798,809		$	21.93		8.20	$	10,700
Options granted		226,663			49.80		9.25		209
Options exercised		(210,199	)		14.93		N/A		4,994
Options cancelled		(77,851	)		27.85		N/A		N/A
Options outstanding at December 31, 2014		737,422			32.19		8.09		14,512
Options granted		190,900			62.37		9.68		1,148
Options exercised		(49,045	)		23.66		N/A		5,197
Options cancelled		(88,264	)		47.86		N/A		N/A
Options outstanding at June 30, 2015		791,013		$	40.28		8.09	$	23,104
Options exercisable at December 31, 2014		91,947		$	28.87		6.30	$	3,326
Options exercisable at June 30, 2015		153,900		$	34.84		6.60	$	6,941

Restricted stock activity during 2014 and 2015 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		461,697		$	24.96
Granted		468,484			48.99
Cancelled		(75,369	)		36.36
Vested		(132,784	)		22.81
Unvested at December 31, 2014		722,028		$	39.77
Granted		480,152			62.08
Cancelled		(55,674	)		49.59
Vested		(107,263	)		32.47
Unvested at June 30, 2015		1,039,243		$	51.03

Restricted stock unit activity during 2014 and 2015 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2014		95,751		$	23.05
Granted		108,449			50.75
Cancelled		—			—
Vested		(79,087	)		21.81
Unvested at December 31, 2014		125,113		$	38.73
Granted		217,994			61.77
Cancelled		—			—
Vested		(125,023	)		32.38
Unvested at June 30, 2015		218,084		$	56.97

The grant-date fair value of the Company’s stock options is estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the six months ended June 30, 2015 and year ended December 31, 2014:

	June 30, 2015			December 31, 2014
Weighted average grant-date fair value of options	$	24.30		$	17.14
Risk-free interest rate		1.9	%		1.7	%
Expected volatility		33	%		36	%
Expected life (in years)		5.5			5.5

The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies given the lack of sufficient historical trading experience of the Company’s common stock. The risk-free interest rate is the approximate yield on United States Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

XML

Derivatives - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jul. 01, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
(Losses) gains associated with changes in fair value of the foreign currency forward contracts	$ (1.0)	$ 13.7	$ (0.9)	$ 13.7
Settlement of foreign currency forward contracts					$ 15.3

XML

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Jul. 01, 2014	Mar. 12, 2013	Nov. 01, 2011
Disclosures Regarding Financial Instruments [Line Items]
Contingent consideration, Paid		$ 3,250
Park Royal [Member]
Disclosures Regarding Financial Instruments [Line Items]
Increase (Decrease) in fair value of contingent consideration liability	$ 500
Contingent consideration, Paid			$ 5,000
Contingent consideration liabilities			7,000
McCallum [Member]
Disclosures Regarding Financial Instruments [Line Items]
Cash payments for earn-out agreement			$ 6,000
12.875% Senior Notes Due 2018 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	12.875%		12.875%		12.875%	12.875%
6.125% Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	6.125%		6.125%		6.125%
5.125% Senior Notes due 2022 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.125%		5.125%	5.125%
5.625 % Senior Notes Due 2021 [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	5.625%
9.0% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.00%		9.00%
9.5% Revenue Bonds [Member]
Disclosures Regarding Financial Instruments [Line Items]
Debt instrument interest rate	9.50%		9.50%

XML

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Effective tax rates	31.40%	39.90%	31.40%	39.00%

XML

Description of Business and Basis of Presentation - Additional Information (Detail) - Jun. 30, 2015	Beds State Facilities
Accounting Policies [Abstract]
Number of facilities | Facilities	223
Number of beds | Beds	9,000
Number of operating states	37
Percentage of ownership in subsidiaries	100.00%

XML

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($)						3 Months Ended				6 Months Ended		13 Months Ended	17 Months Ended
	Dec. 15, 2014	Jun. 16, 2014	Feb. 13, 2014	Dec. 31, 2012	Apr. 01, 2011	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Feb. 12, 2014	Jun. 30, 2015	Feb. 11, 2015	Feb. 06, 2015
Debt Instrument [Line Items]
Quarterly term loan principal payment										$ 180,000,000	$ 113,000,000
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement	Dec. 15, 2014		Feb. 13, 2014	Dec. 31, 2012	Apr. 01, 2011
Amount available under revolving line of credit										$ 291,100,000			$ 291,100,000
Debt instrument maturity date	Feb. 13, 2019									Feb. 11, 2022
Quarterly term loan principal payment	$ 1,900,000
Term loan repayments						$ 1,300,000
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA	40,000,000
Commitment fee for undrawn amounts												0.50%	0.40%
Amended and Restated Senior Credit Facility [Member] | Miscellaneous Investments [Member]
Debt Instrument [Line Items]
Date entered into an agreement		Jun. 16, 2014
Restrictive covenants on investments, Description										The Company may now invest, in any given fiscal year, up to five percent (5%) of its total assets in both joint ventures and foreign subsidiaries, respectively; provided that the aggregate amount of investments in both joint ventures and foreign subsidiaries, respectively, may not exceed ten percent (10%) of its total assets over the life of the Amended and Restated Senior Credit Facility; provided further that the aggregate amount of investments made in both joint ventures and foreign subsidiaries collectively pursuant to the foregoing may not exceed fifteen percent (15%) of its total assets.
Amended and Restated Senior Credit Facility [Member] | Scenario, Plan [Member]
Debt Instrument [Line Items]
Additional term loans			$ 150,000,000
Line of Credit Facility, Increase (Decrease) for Period, Description										The Fourth Amendment also provides for a $150.0 million incremental credit facility, with the potential for unlimited additional incremental amounts, provided the Company meets certain financial ratios, in each case subject to customary conditions precedent to borrowing.
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Line of credit			300,000,000
Additional term loans	235,000,000
Amended and Restated Senior Credit Facility [Member] | Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit			$ 300,000,000
Amended and Restated Senior Credit Facility [Member] | Seventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement										Feb. 06, 2015
Amended and Restated Senior Credit Facility [Member] | Letter of Credit [Member] | Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit															$ 20,000,000
Amended and Restated Senior Credit Facility [Member] | Swing Line Sublimit [Member] | Seventh Amendment [Member]
Debt Instrument [Line Items]
Line of credit															$ 20,000,000
Amended and Restated Senior Credit Facility [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings										3.25%
Basis spread on variable rate										1.00%
Amended and Restated Senior Credit Facility [Member] | Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings										2.25%
Basis spread on variable rate										0.50%
Amended and Restated Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings										3.25%
Amended and Restated Senior Credit Facility [Member] | Senior Debt Obligations [Member] | First Incremental Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement										Feb. 11, 2015
Line of credit														$ 500,000,000
Amended and Restated Senior Credit Facility [Member] | June 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	6,700,000
Term loan repayments									$ 1,300,000
Amended and Restated Senior Credit Facility [Member] | March 31, 2016 to December 31, 2016 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	10,000,000
Term loan repayments								$ 1,300,000
Amended and Restated Senior Credit Facility [Member] | March 31, 2017 to December 31, 2017 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	13,400,000
Term loan repayments							$ 1,300,000
Amended and Restated Senior Credit Facility [Member] | March 31, 2018 to December 31, 2018 [Member]
Debt Instrument [Line Items]
Term loan principal repayments	16,700,000
Amended and Restated Senior Credit Facility [Member] | CRC Health Group, Inc [Member] | Senior Secured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Temporary reserve	$ 110,000,000

XML

Segment Information

6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Segment Information

13. Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilities in the United States (the “U.S. Facilities”) and its facilities in the United Kingdom (the “U.K. Facilities”) separately to assess performance and make decisions, the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At June 30, 2015, the U.S. Facilities included 178 behavioral healthcare facilities with approximately 7,200 beds in 37 states and Puerto Rico, and the U.K. Facilities included 45 behavioral healthcare facilities with approximately 1,800 beds in the United Kingdom.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Revenue:
U.S. Facilities	$	366,886		$	212,834		$	657,393		$	413,398
U.K. Facilities		84,927			—			158,242			—
Corporate and Other		1,847			969			3,808			1,823
	$	453,660		$	213,803		$	819,443		$	415,221
Segment EBITDA (1):
U.S. Facilities	$	102,342		$	53,031		$	178,706		$	100,563
U.K. Facilities		20,371			—			39,182			—
Corporate and Other		(16,910	)		(8,317	)		(33,373	)		(16,567	)
	$	105,803		$	44,714		$	184,515		$	83,996

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Segment EBITDA (1)	$	105,803		$	44,714		$	184,515		$	83,996
Plus (less):
Equity-based compensation expense		(5,355	)		(2,406	)		(9,249	)		(4,170	)
(Loss) gain on foreign currency derivatives		(961	)		13,735			(908	)		13,735
Transaction-related expenses		(7,157	)		(3,016	)		(25,573	)		(4,595	)
Interest expense, net		(28,049	)		(9,730	)		(50,195	)		(19,437	)
Depreciation and amortization		(14,926	)		(5,935	)		(28,030	)		(11,371	)
Income from continuing operations before income taxes	$	49,355		$	37,362		$	70,560		$	58,158

	U.S. Facilities		U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2015	$	693,945	$	109,041		$	—	$	802,986
Increase from 2015 acquisitions		1,103,813		65,293			—		1,169,106
Foreign currency translation		—		6,972			—		6,972
Purchase price allocation and other		281		(33,317	)		—		(33,036	)
Balance at June 30, 2015	$	1,798,039	$	147,989		$	—	$	1,946,028

	June 30, 2015		December 31, 2014
Assets (2):
U.S. Facilities	$	2,729,896	$	1,327,563
U.K. Facilities		944,033		726,693
Corporate and Other		252,456		169,334
	$	3,926,385	$	2,223,590

(1) Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, gain/loss on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2) Assets include property and equipment for the U.S. Facilities of $671.2 million, U.K. Facilities of $754.2 million and corporate and other of $30.0 million at June 30, 2015. Assets include property and equipment for the U.S. Facilities of $478.1 million, U.K. Facilities of $578.6 million and corporate and other of $13.0 million at December 31, 2014.

XML

Acquisitions (Tables)

6 Months Ended

Jun. 30, 2015

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the year ended December 31, 2014 in connection with the 2014 acquisitions were as follows (in thousands):

	Partnerships in Care		Other		Total
Cash	$	11,674	$	—	$	11,674
Accounts receivable		7,684		1,849		9,533
Prepaid expenses and other current assets		8,828		169		8,997
Property and equipment		610,477		27,203		637,680
Goodwill		87,047		32,232		119,279
Intangible assets		651		204		855
Other assets		7,037		3,240		10,277
Total assets acquired		733,398		64,897		798,295
Accounts payable		3,958		93		4,051
Accrued salaries and benefits		10,422		—		10,422
Other accrued expenses		7,166		1,014		8,180
Deferred tax liabilities – noncurrent		15,597		—		15,597
Other liabilities		7,704		—		7,704
Total liabilities assumed		44,847		1,107		45,954
Net assets acquired	$	688,551	$	63,790	$	752,341

Transaction Related Expenses as Incurred

Transaction-related expenses comprised the following costs for the three and six months ended June 30, 2015 and 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Advisory and financing commitment fees	$	—	$	—	$	10,337	$	—
Legal, accounting and other costs		5,234		3,016		9,054		4,136
Severance and contract termination costs		1,923		—		6,182		459
	$	7,157	$	3,016	$	25,573	$	4,595

Pro Forma Financial Information for Acquisitions Occurred

The following table provides certain pro forma financial information for the Company as if the 2014 and 2015 Acquisitions occurred as of January 1, 2014 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Revenue	$	461,128	$	431,663	$	901,582	$	841,767
Income from continuing operations, before income taxes	$	51,123	$	32,289	$	39,293	$	31,198

Crc Health Group Inc and Other Acquisitions [Member]

Preliminary Fair Values of Assets Acquired and Liabilities Assumed at Corresponding Acquisition Date

The preliminary fair values of assets acquired and liabilities assumed, at the corresponding acquisition dates, during the six months ended June 30, 2015 in connection with the 2015 acquisitions were as follows (in thousands):

	CRC		Other		Total
Cash	$	19,600	$	4,468	$	24,068
Accounts receivable		47,095		6,130		53,225
Prepaid expenses and other current assets		25,522		1,380		26,902
Property and equipment		140,152		138,613		278,765
Goodwill		1,050,620		118,486		1,169,106
Intangible assets		37,000		—		37,000
Deferred tax assets – noncurrent		64,688		—		64,688
Other assets		6,478		—		6,478
Total assets acquired		1,391,155		269,077		1,660,232
Accounts payable		5,301		7,114		12,415
Accrued salaries and benefits		14,860		1,642		16,502
Other accrued expenses		38,703		2,546		41,249
Deferred tax liabilities – noncurrent		—		1,052		1,052
Long-term debt		904,467		—		904,467
Other liabilities		34,248		11		34,259
Total liabilities assumed		997,579		12,365		1,009,944
Net assets acquired	$	393,576	$	256,712	$	650,288

XML

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 1,953,207	$ 1,096,270
Long-term debt	1,953,207	1,096,270
Less: current portion	(38,652)	(26,965)
Long-term debt	1,914,555	1,069,305
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term A Loans [Member]
Debt Instrument [Line Items]
Senior Secured	512,497	525,576
Amended and Restated Senior Credit Facility [Member] | Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	495,123
12.875% Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]
Senior Notes	96,533	96,420
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	375,000
9.0% and 9.5% Revenue Bonds [Member]
Debt Instrument [Line Items]
9.0% and 9.5% Revenue Bonds	$ 24,054	$ 24,274

XML

Acquisitions - Summary of Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 1,946,028	$ 802,986
Domestic Acquisitions in 2015 and 2014 [Member]
Business Acquisition [Line Items]
Goodwill associated with domestic acquisitions	$ 175,500	$ 175,500

XML

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Equity-based compensation expense	$ 5,355	$ 2,406	$ 9,249	$ 4,170

XML

Earnings Per Share

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share

2. Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities have a dilutive effect on earnings per share.

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2015 and 2014 (in thousands except per share amounts):

	Three Months Ended June 30,					Six Months Ended June 30,
	2015		2014			2015		2014
Numerator:
Basic and diluted earnings per share:
Income from continuing operations	$	33,843	$	22,457		$	48,435	$	35,478
Income (loss) from discontinued operations		1		(6	)		3		31
Net income	$	33,844	$	22,451		$	48,438	$	35,509
Denominator:
Weighted average shares outstanding for basic earnings per share		68,296		51,616			65,429		50,872
Effect of dilutive instruments		439		203			353		302
Shares used in computing diluted earnings per common share		68,735		51,819			65,782		51,174
Basic earnings per share:
Income from continuing operations	$	0.50	$	0.43		$	0.74	$	0.70
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.50	$	0.43		$	0.74	$	0.70
Diluted earnings per share:
Income from continuing operations	$	0.49	$	0.43		$	0.74	$	0.69
Income (loss) from discontinued operations		—		—			—		—
Net income	$	0.49	$	0.43		$	0.74	$	0.69

Approximately 0.3 million and 0.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended June 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive. Approximately 0.9 million and 0.5 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the six months ended June 30, 2015 and 2014, respectively, because their effect would have been anti-dilutive.

XML

Equity-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	4,700,000		4,700,000
Equity incentive plan available for future grant	1,257,326		1,257,326
Annual increments in employee grants			25.00%
Stock options, contractual term			10 years
Equity-based compensation expense	$ 5,355	$ 2,406	$ 9,249	$ 4,170
Unrecognized compensation expense related to unvested options			$ 57,700
Vesting period			1 year 7 months 6 days
Warrants outstanding	0		0
Tax realized from stock options exercised	$ 2,000	800	$ 6,300	3,500
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 2,200	$ 1,000	$ 3,800	$ 1,700

XML

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015 USD ($)
Goodwill:
Beginning balance	$ 802,986
Increase from 2015 acquisitions	1,169,106
Foreign currency translation	6,972
Purchase price allocation and other	(33,036)
Ending balance	1,946,028
U.S. Facilities [Member]
Goodwill:
Beginning balance	693,945
Increase from 2015 acquisitions	1,103,813
Purchase price allocation and other	281
Ending balance	1,798,039
U.K. Facilities [Member]
Goodwill:
Beginning balance	109,041
Increase from 2015 acquisitions	65,293
Foreign currency translation	6,972
Purchase price allocation and other	(33,317)
Ending balance	$ 147,989

XML

Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	June 30, 2015		December 31, 2014		June 30, 2015			December 31, 2014
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(1,540	)	$	(1,330	)
Non-compete agreements		1,247		1,247		(1,205	)		(1,155	)
		3,347		3,347		(2,745	)		(2,485	)
Intangible assets not subject to amortization:
Licenses and accreditations		10,318		9,184		—			—
Trade names		37,800		3,000		—			—
Certificates of need		9,794		8,590		—			—
		57,912		20,774		—			—
Total	$	61,259	$	24,121	$	(2,745	)	$	(2,485	)

XML

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 34,572	$ 94,040	$ 277,744	$ 4,569
Accounts receivable, net	182,315	118,378
Deferred tax assets	38,693	20,155
Other current assets	70,325	41,570
Total current assets	325,905	274,143
Property and equipment, net	1,455,390	1,069,700
Goodwill	1,946,028	802,986
Intangible assets, net	58,514	21,636
Deferred tax assets - noncurrent	33,966	13,141
Other assets	106,582	41,984
Total assets	3,926,385	2,223,590
Current liabilities:
Current portion of long-term debt	38,652	26,965
Accounts payable	58,714	48,696
Accrued salaries and benefits	77,545	59,317
Other accrued liabilities	68,197	30,956
Total current liabilities	243,108	165,934
Long-term debt	1,914,555	1,069,305
Deferred tax liabilities - noncurrent	20,200	63,880
Other liabilities	82,218	43,506
Total liabilities	2,260,081	1,342,625
Total equity	1,666,304	880,965
Total liabilities and equity	3,926,385	2,223,590
Consolidating Adjustments [Member]
Current assets:
Cash and cash equivalents				(1,925)
Deferred tax assets - noncurrent		(5,666)
Investment in subsidiaries	(1,332,308)	(1,759,337)
Other assets	(351,373)	(181,774)
Total assets	(1,683,681)	(1,946,777)
Current liabilities:
Long-term debt	(351,373)	(181,774)
Deferred tax liabilities - noncurrent		(5,666)
Total liabilities	(351,373)	(187,440)
Total equity	(1,332,308)	(1,759,337)
Total liabilities and equity	(1,683,681)	(1,946,777)
Parent [Member]
Current assets:
Deferred tax assets - noncurrent	5,361	4,563
Investment in subsidiaries	1,332,308	1,759,337
Other assets	389,676	202,708
Total assets	1,727,345	1,966,608
Current liabilities:
Current portion of long-term debt	38,437	26,750
Other accrued liabilities	22,604	13,647
Total current liabilities	61,041	40,397
Long-term debt		1,045,246
Total liabilities	61,041	1,085,643
Total equity	1,666,304	880,965
Total liabilities and equity	1,727,345	1,966,608
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	17,179	76,685	274,517
Accounts receivable, net	160,179	100,797
Deferred tax assets	36,502	18,395
Other current assets	62,295	36,049
Total current assets	276,155	231,926
Property and equipment, net	656,262	451,943
Goodwill	1,700,705	596,611
Intangible assets, net	55,928	19,057
Deferred tax assets - noncurrent	16,239
Other assets	65,957	18,727
Total assets	2,771,246	1,318,264
Current liabilities:
Accounts payable	44,985	39,486
Accrued salaries and benefits	65,040	47,597
Other accrued liabilities	27,543	7,688
Total current liabilities	137,568	94,771
Long-term debt	1,890,716
Deferred tax liabilities - noncurrent		21,027
Other liabilities	72,329	33,321
Total liabilities	2,100,613	149,119
Total equity	670,633	1,169,145
Total liabilities and equity	2,771,246	1,318,264
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	17,393	17,355	$ 3,227	$ 6,494
Accounts receivable, net	22,136	17,581
Deferred tax assets	2,191	1,760
Other current assets	8,030	5,521
Total current assets	49,750	42,217
Property and equipment, net	799,128	617,757
Goodwill	245,323	206,375
Intangible assets, net	2,586	2,579
Deferred tax assets - noncurrent	12,366	14,244
Other assets	2,322	2,323
Total assets	1,111,475	885,495
Current liabilities:
Current portion of long-term debt	215	215
Accounts payable	13,729	9,210
Accrued salaries and benefits	12,505	11,720
Other accrued liabilities	18,050	9,621
Total current liabilities	44,499	30,766
Long-term debt	375,212	205,833
Deferred tax liabilities - noncurrent	20,200	48,519
Other liabilities	9,889	10,185
Total liabilities	449,800	295,303
Total equity	661,675	590,192
Total liabilities and equity	$ 1,111,475	$ 885,495

XML

Acquisitions - Recent Acquisitions (Detail) - Mar. 01, 2015 - Quality Addiction Management [Member] $ in Millions	USD ($) Center
Business Acquisition [Line Items]
Business acquisition cash paid | $	$ 54.6
Number of facilities acquired	7

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. Commitments and Contingencies

The Company is, from time to time, subject to various claims and legal actions that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In the opinion of management, the Company is not currently a party to any proceeding that would individually or in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.